Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksManolete Partn. Regulatory News (MANO)

Share Price Information for Manolete Partn. (MANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 127.50
Bid: 120.00
Ask: 135.00
Change: 0.00 (0.00%)
Spread: 15.00 (12.50%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 127.50
MANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Results

3 Jul 2020 07:00

RNS Number : 9207R
Manolete Partners PLC
03 July 2020
 

3 July 2020

 

MANOLETE PARTNERS PLC

("Manolete" or the "Company")

 

Audited results for the year ended 31 March 2020

 

Manolete (AIM:MANO), the UK's leading listed insolvency litigation financing company, today announces its audited results for the year ended 31 March 2020.

Steven Cooklin, Chief Executive Officer, commented: "We have delivered another set of strong financial and operating results, with impressive double-digit growth in revenue and EBIT during the period. We continue to deliver outstanding investment returns, yielding an average Money Multiple of 2.7x and ROI of 174% on 257 completed cases since inception.

"Despite the large expansion of the infrastructure overhead required for the rapid expansion of the business in FY20, Company net cash receipts from completed cases (after all payments to Insolvency Practitioners and lawyers' fees on those cases) exceeded all Company overhead costs. We are currently running a record 201 live cases and foresee no requirement for any further material increase in overhead costs, so the outlook for cash generation is very positive.

"Despite the challenges of COVID-19, the activity levels within the business are at record levels, highlighted by the 47 new case investments (124% more than the same period last year) and 23 case completions (up from four in the same period last year) that the team has transacted in the first quarter of FY21. New case enquiries are also at all-time record levels, running at around double the rate we had this time last year. We entered FY21 with £8.4m of gross cash, a positive net cash balance and £12m of our HSBC Revolving Credit Facility unutilised. All these factors firmly underpin our confidence in the current and future trading performance of the business.

"With the widely reported economic disruption likely to ensue, we expect new case enquiries to increase over the foreseeable future and we will continue working to deliver outstanding returns to both insolvent estates and investors."

Financial (statutory and non-statutory) highlights:

· Revenue increased by 36% to £18.7m (FY19: £13.8m)

· Gross profit up 43% to £14.4m (FY19: £10.1m)

· EBIT pre-exceptionals increased by 36% to £9.8m (FY19: £7.2m)

· Profit before tax (before exceptional IPO costs of £882K in FY19) up 40% to £9.5m (FY19: £6.8m)

· Profit after tax (adjusted for exceptionals) increased by 38% to £7.6m (FY19: £5.5m)

· Diluted earnings per share up 70% to 17 pence (FY19: 10 pence)

· Proposed final dividend of 3.0 pence per share, 100% increase on FY19 final dividend of 1.49p

· Investment in cases up 78% to £32.4m (FY19: £18.2m)

· Cash generation: cash receipts from completed cases exceeded all completed case legal costs, all payments to Insolvency Practitioners on completed cases and all Company overheads in FY20

· Operating cashflows before movements in working capital pre new investments (non-statutory layout) increased to £1.2m in FY20 (FY19: £0.7m) hence cash inflows from completed cases exceeded payments to lawyers and IPs incurred on those cases and all overhead payments

· Gross cash of £8.4m and borrowings of £7.5m as at 31 March 2020 and £12m borrowings available on Revolving Credit Facility with HSBC

 

 

Operational highlights:

· 139% increase in new core investments in UK insolvency cases: 141 in FY20 (FY19: 59), excluding two Cartel Cases in FY19

· Ongoing delivery of realised returns: 54 case realisations in FY20 (on average one case realisation per week) with an average duration on those 54 cases of 11 months, generating a 10% increase in gross proceeds to £10.2m (FY19: 35 case realisations generating gross proceeds of £9.3m of Company cash income)

· ROI of 173% and Money Multiple of 2.7x from 257 completed cases since inception

· 33 cases already completed in the FY20 vintage at a Money Multiple of 4.6x

· Average case duration across the full portfolio of 257 completed cases is 12 months

· 81% increase in live cases: 152 in process as at 31 March 2020 (84 as at 31 March 2019)

· Over 200 live cases currently in process

· Roll-out of regional network completed with in-house lawyers recruited in: North West, South West & Wales, Eastern, North East, Midlands, London, Southern and Scottish regions of the UK

· New case enquiries at all-time record levels

· 47 new case investments made and 23 cases already completed in FY21 to date

A copy of the annual report and accounts will be available on the Company's website shortly and will be posted to shareholders in due course. 

Manolete has today appointed Liberum Capital Limited as joint broker to the Company.

 

For further information please contact:

Manolete Partners

Steven Cooklin (Chief Executive Officer) via Instinctif Partners

 

Peel Hunt (NOMAD and Joint Broker) +44 (0)20 7418 8900

James Britton

Rishi Shah

Duncan Littlejohns

 

Liberum (Joint Broker) +44 (0)20 3100 2000

Richard Crawley

James Greenwood

 

Instinctif Partners

Tim Linacre +44 (0)7949 939237

Catherine Wickman +44 (0)7739 342009

Lewis Hill +44 (0)7837 674600

 

 

Chairman's Statement

 

Overview

 

I am pleased to report that the Company has seen excellent growth over the past year with 141 new case investments in the year to 31 March 2020.

 

The Company's results reflect the strength, resilience and capabilities of the business, as it continues to increase the number and average size of new case investments through its expanding network of Insolvency Practitioners and Insolvency Lawyers throughout the UK.

 

Financial results

 

The business achieved impressive growth in the year ended 31 March 2020, with revenues increasing by 36% to £18.7 million (FY19: £13.8m) and Profit before Tax growing by 61% to £9.5 million (FY19: £5.9m).

 

The Company has achieved this growth through its regional network of in-house lawyers, the successful deployment of the funds raised through the HSBC credit facility and the IPO, the Company's increased public profile following the IPO and the continued hard work of the team.

 

Strategy

 

We remain focused on strengthening the profile of Manolete, as we continue to increase the number and average size of cases within our insolvency litigation investment portfolio.

 

An important component to our strategy is to build upon our ever-growing network of established Insolvency Practitioner and Insolvency Lawyer contacts throughout the UK. We have been strengthening the team, and now have 11 high quality in-house lawyers in different regions across the UK. As a result, we have seen a significant increase in the volume of enquires.

 

Dividend

 

The Board has adopted a progressive dividend policy based on a pay-out ratio of 20% of profit after tax, with one third being paid as an interim dividend and two thirds as a final dividend. For the year to 31 March 2020 the Board is proposing a final dividend of 3.00p per share. Subject to the approval of Shareholders at the Annual General Meeting on 22 September 2020, the dividend to Ordinary Shareholders will be payable on 30 September to those shareholders who are on the register of members at 11 September 2020.

 

Corporate Governance

The Board of Directors is committed to good corporate governance. The Company has adopted the ten principles of the 2018 Version of the Corporate Governance Code as set out by the Quoted Companies Alliance. Our arrangements are further described in our Corporate Governance Statement on pages 24 to 28. During the year the Board undertook its first formal board evaluation exercise.

The Audit Committee report on pages 29 to 30 and the Remuneration Committee report on pages 31 to 34 describe the remits and approaches of those committees to fulfilling their governance responsibilities. A statement on corporate governance is also provided on our website (https://investors.manolete-partners.com/company-information/corporate-governance).

People

On behalf of the Board and Shareholders I would like to thank our staff for their commitment and hard work during the year.

 

Board

 

On 1 October 2019 we announced that Patrick Lineen decided to retire on 27 November 2019 and the Board are grateful to Patrick for assisting us through the IPO process. We are delighted to welcome Mark Tavener to the Manolete Board as Chief Financial Officer, who joined the Company and the Board on 7 October 2019.

 

Outlook

 

Despite COVID-19, activity levels in April, May and June 2020 have remained strong with new case referrals of 186 compared to last year's total of 98. The team are currently running a record 200 live cases. We are confident that our portfolio of cases will provide attractive returns for shareholders. Overall, the business is very well-positioned in the insolvency litigation financing market for long-term profitable growth.

 

Peter Bertram

Non-Executive Chairman

 

CEO Statement

 

I am pleased to report on a significant year of growth and delivery to shareholders for the financial year ended 31 March 2020.

Operational Progress since IPO on AIM

FY20 represents the Company's first full year of trading as a publicly listed company on AIM. The proceeds from the successful IPO in December 2018 and the increased HSBC £20m Revolving Credit Facility have enabled us to rapidly expand the business.

Manolete has completed the first phase in the establishment of its proprietary UK network of in-house lawyers. We now have our own expert in-house insolvency litigators based in all key regions of the UK: North East, North West, Midlands, East of England, South and South East, South West and Wales, London and Scotland. We have an additional part-time consultant in the important Midlands market and have signed contracts for an additional part-time consultant to cover the Leeds market. Despite the network being established in a relatively short period, we are delighted to report that we have recorded a 100% retention rate for these employees. Most of the new joiners were already well known to us, having acted for us on cases prior to joining the Company.

The solicitors we have hired are all highly experienced insolvency lawyers, most were at Partner level within their respective legal practices. In time, the next stage of the regional expansion will be primarily aimed at hiring more junior lawyers to support the regional heads.

We currently have 11 in-house lawyers. We estimate each in-house lawyer can supervise around 25 live cases at any one time (as the large majority of the legal work on our cases is undertaken by external solicitors and barristers). This gives the Company capacity to manage around 275 live cases at any one time. At the time of writing we have 200 live cases, so the Company already has the infrastructure in place for its next stage of growth before any step change in the overhead base is likely to be required.

The IPO proceeds, together with our draw down of £8m of our £20m HSBC Revolving Credit Facility, has given us the financial firepower to take on a higher number of cases and larger cases, without fear of portfolio concentration risk. Our publicly listed status has also raised our profile, stature and credibility in the professional networks we operate in. As evidenced in Professor Walton's recent report on the Insolvency Litigation Funding Sector, that we commissioned, Manolete is by far the dominant player in the Third Party Finance ('TPF') sector of the market, commanding a 67% market share of that segment (up from 52% in April 2016). The market as a whole, with an aggregate annual headline claim value of around £1.5bn, is still majority financed using the old 'Conditional Fee Agreement/After The Event Insurance' policy model. However, as Professor Walton stated, this situation is being "turned on its head" with the rapid increase in the TPF share. Further progress in this area is the core growth opportunity for the Company.

Strong Operating and Financial Performance

Quarterly number of

new enquiries

 

 

 

Q1 2017

36

Q2 2017

47

Q3 2017

46

Q4 2017

69

Q1 2018

39

Q2 2018

60

Q3 2018

75

Q4 2018

66

Q1 2019

66

Q2 2019

72

Q3 2019

53

Q4 2019

76

Q1 2020

98

Q2 2020

99

Q3 2020

115

Q4 2020

181

 

Quarterly number of signed cases

 

 

 

Q1 2017

5

Q2 2017

7

Q3 2017

10

Q4 2017

9

Q1 2018

6

Q2 2018

15

Q3 2018

15

Q4 2018

14

Q1 2019

11

Q2 2019

20

Q3 2019

9

Q4 2019

21

Q1 2020

21

Q2 2020

44

Q3 2020

32

Q4 2020

44

 

 

Manolete has delivered another positive operating and financial performance this financial year. Operating profit increased by 36% to £9.8m (FY19: £7.2m), which was driven by the following factors.

New case investments increased by over 139% to 141 in FY20 (FY19: 59, excluding the two Cartel Cases which were purchased in FY19).

To date, we have invested in a total of 462 cases over the lifetime of the Company (262 of which have been completed - three of which are partially completed).

New case completions in FY20 were also at a high level, resulting in an 10% increase in gross proceeds from completed cases - 54 completed cases in FY20 generating £10.2m of gross proceeds (FY19: £9.3m from 35 completed cases).

This means that Manolete was completing, on average, a case every week throughout the year, which highlights the impressive speed of completion under our bespoke insolvency litigation finance model. Our strategic preference is to purchase rather than fund cases, which gives our Insolvency Practitioner clients and the insolvent estate full effective protection from any potential adverse costs, as well as providing the Company with full operational control of the case through the litigation process. However, whether funding or buying the claims, we are always working in a team with the IP and the lawyers.

Before investments in new cases, the cash receipts from older cases (predominantly from the FY18 and FY19 vintages) in FY20 exceeded all Company overhead costs as well as all payments to Insolvency Practitioners and lawyers on those closed cases. With a far greater number of cases (and generally larger cases) either recently completed or in progress, the outlook for further increased material cash generation from the portfolio appears very encouraging. In FY20 there was a step-change in overheads from £2.8m to £4.6m mainly due to the increased in-house lawyer headcount, but that now gives us the capacity to manage up to around 275 live cases (currently 200 live case) therefore we do not foresee any need for a material increase in overheads in the immediate future.

 

The Cartel Cases continue to progress well. Our external legal team has completed their Phase Two work and is now working to complete fully particularised claims supported by an expert economic valuation and evidence report over the next phase of work, with a view to issuing the claims in due course. The focus remains on the two particularly large Cartel Cases (CityLink and Comet) which were purchased for £100,000 and £125,000 respectively, but in both of these cases, Manolete has a 90% profit share on the claims. The other cases are much smaller and therefore our valuation of the Cartel Cases as a group is solely based on the two much larger cases at this stage. By focussing on just two cases, an additional benefit is that the legal and expert work on the lower volume of claims is considerably reduced.

The overall Cartel Cases opportunity remains highly attractive. To reflect our increased confidence in the final outcome of these cases as a group of claims, as at 31 March 2020 we have increased our carrying value of the cases to a combined £7.1m (FY19: £5m). The final outcome on the Cartel Cases is hoped to be a multiple of the carrying value, but there is still much work to do to bring these cases to final fruition.

Investment Returns

Our investment track record, by vintage, continues to deliver outstanding results. All vintages up to and including FY16 have been completed and FY17 has only one case remaining. FY18 cases are 79% complete, as are well over half of the FY19 cases. Manolete's model is characterised by short case durations, high ROIs (Return on Investment), exceptional Money Multiples and very high IRRs. We calculate case duration from the date we sign the investment agreement to the date the case is legally concluded.

 

Financial Year

#

Number

%

Number

Open Cases

Closed Case

Total

Total

Total

IP Share

Manolete

Duration

ROI

MoM

IRR

 

Investments

Completed

Completion

Outstanding

Investments

Investments

Invested

Recovered

Gain

 

Gain

Completed Cases

 

 

 

 

 

 

 

 

£000s

£000s

£000s

£000s

£000s

£000s

£000s

(Months)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2010

3

3

100%

-

-

52

52

28

(24)

-

(24)

7

-46%

0.5

0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2011

-

-

100%

-

-

-

-

-

-

-

-

-

0%

0.0

0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2012

8

8

100%

-

-

763

763

2,524

1,761

580

1,181

18

155%

2.5

236%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2013

10

10

100%

-

-

174

174

780

606

316

290

7

167%

2.7

281%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2014

42

42

100%

-

-

594

594

3,884

3,290

2,427

863

10

145%

2.5

424%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2015

39

39

100%

-

-

1,476

1,476

7,029

5,553

3,290

2,263

13

153%

2.5

526%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2016

36

36

100%

-

-

1,907

1,907

9,009

7,102

4,123

2,979

15

156%

2.6

176%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2017

31

30

97%

1

246

1,086

1,332

4,555

3,469

2,037

1,432

12

132%

2.3

609%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2018

29

23

79%

6

1,335

560

1,895

4,276

3,716

2,423

1,293

11

231%

3.3

1149%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019

59

33

56%

26

804

681

1,485

3,116

2,435

1,310

1,125

9

165%

2.7

165%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020

141

33

23%

108

1,657

727

2,384

6,194

5,467

2,875

2,592

6

357%

4.6

1010%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

398

257

65%

141

4,042

8,020

12,062

41,395

33,375

19,381

13,994

12

174%

2.7

133%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*includes cases completed since the year-end

** only refers to completed cases

*** excludes impact of Bright Futures as not reported until Friday 26th June in vintage FY18

The number of completed cases in 2020 includes three partially completed cases (a case is partially complete when we have achieved a material resolution with some but not all potential defendants).

Given the record level of new case investments, the level of unrealised profit is naturally higher than usual this year. However, the FY20 vintage (all invested since the IPO) already shows excellent returns. The 33 cases already completed have delivered £6.2m in gross recoveries which is higher than the gross proceeds of the 2019, 2018 and 2017 vintages. The completed cases from this FY20 vintage currently shows a much higher Money Multiple at 4.6x and record Return of Investment at 357%. Durations of cases remain low, all of which demonstrates the inherent robustness of the business model and the strong execution of the Company's strategy since the IPO.

The 33 case completions of the FY20 vintage to date have generated average total recoveries of £188k per case compared to £94k per case for the FY19 vintage of 33 completed cases. This represents a 94% increase in average recovery per case, evidencing the increase in average size per case as the business continues to gain further traction and maturity in the UK insolvency litigation finance market.

During our 11 year history more than 95% of our 263 completed cases have resolved pre-trial, so it was unusual to have three trials completed on older cases (two from FY 18 and one from FY19) within the last few weeks, after the year end. This was the reason we moved our annual results reporting date. In two cases we won on all heads of claim and the awards were at or in excess of that assumed within our Fair Value calculations as at 31 March 2020. The trials of these two cases took place in May hence there is no adjustment to the year end valuation. The third case (Bright Futures) trial took place and completed during March but only 'handed down' its verdict on 26th June. It involved heads of claim totalling c. £7m but held at only £395k Fair Value in our balance sheet. We were only successful on one of the smaller three heads of claim. The FY20 audited accounts therefore reflect a write-down of the Fair Value and the costs associated with this case. The total adverse effect to pre-tax profits from this case are £709k. An appeal on this case is now being considered. Going forward, we expect the percentage of cases that settle pre-trial to remain at around the same historic 95% level.

Walton Report 2020

Professor Peter Walton's (University of Wolverhampton) report: Insolvency Litigation Funding - in the best interests of creditors? examined the impact of the 'Jackson Reforms' on the insolvency litigation market including survey data from 173 Insolvency Practitioners.

In the report, Professor Walton said funding was now an integral and important part of the insolvency litigation market which had increased by 50% since 2015 to £1.5b per annum. He detected a substantial shift to financing cases by third parties from 'no-win no-fee' methods. The total claims being pursued in the third-party financing market was estimated to be in the region of £50m and Manolete Partners Plc held a 67% share of it.

COVID-19 Impact and Current Trading

As we have reported to the market, since the COVID-19 crisis emerged, the business has transitioned very well to the rapidly changing UK business operating environment. The Board took the decision to request all staff to work from home a week before the UK Government announced the national lockdown on 23 March 2020. Our regional team have always largely worked from home and the London team transitioned seamlessly. Our work lends itself particularly well to the new environment: almost all cases come to us in electronic format; our settlement meetings (Mediations and With Prejudice Settlement Meetings) easily transitioned to online video conference format and the Courts worked very hard to keep trials and hearings on track using online technologies. In common with many other UK companies, as an initial response to the crisis, to ensure that the Company had adequate liquidity to continue purchasing and funding cases at the current high rate of investment, we decided to drawdown £8m of our £20m Revolving Credit Facility.

After a brief pause in mid-March, the case referrals and new case signings bounced back strongly. In the three month period ending 30 June 2020, we received 186 new case referrals, which was 90% higher than the number of referrals for the same period in 2019 (98 case referrals). During the three month period ending 30 June 2020 we signed 47 new case investments, compared to 21 for the same period in 2019, representing a 124% increase.

In the first three months of FY21, we have completed 23 cases (four cases completed in the first three months of FY19) at an average premium of 17% over Fair Values as at 31 March 2020 (excluding Bright Futures). This represents an average of almost two case completions per week which underscores the fast duration and granular composition of the portfolio we are building. At the time of writing, we have over 200 live cases in process, compared with 84 at the end of FY19.

As many have predicted, the COVID-19 crisis is likely to lead to widespread global economic disruption. As we have said previously, we expect there will be an unavoidable knock-on effect for the UK economy and it is likely that this will lead to an increase in case referrals to Manolete in the months to come. 

People and Stakeholders

I am enormously grateful to our in-house legal team and the finance and Net Worth Support team. It has been a very busy year, ending with the challenges of COVID-19. All have performed admirably and are a great credit to the Company. My special thanks go to our Head of Legal, Mena Halton, who has onboarded and supervised a much larger UK-wide in-house legal team, on top of her day-to-day case work. The Company's excellent results are a great reflection of that work.

I would also like to record my thanks to the many Insolvency Practitioners and solicitors who refer cases to us. The majority of invested cases are from the same Insolvency Practitioner firms and it is this recurring referral network that is the core engine of the Manolete business which has been built over the last 11 years.

I am pleased we are delivering on the rapid growth plans set out at and subsequent to our IPO, as we accelerate our growth through investing in more claims, accepting higher value cases and further developing our UK regional network.

 

Steven Cooklin

Chief Executive Officer

2 July 2020

 

CFO Statement

I am pleased to give my review of the Company's audited results for the year to 31 March 2020.

Revenue

The Company's total revenues have increased significantly by 36% to £18.7m (FY19: £13.8m). This revenue is split between realised and unrealised revenue, as follows:

 

FY20

FY19

 

£000s

£000s

Realised revenue

7,782

7,148

Unrealised gains on investments in cases

10,900

6,624

Total

18,682

13,772

 

Realised revenue grew 9% year-on-year to £7.8m (FY19: £7.1m). We have seen a good level of realisations, with 54 cases completing (of which two partially closed) in the year.

As we have executed our regional growth strategy, we have made a record number of new case investments, therefore as expected unrealised gains on investments grew by 65% to £10.9m (FY19: £6.6m). This reflects the progress of existing case investments and new case investments made during the year. New cases increased by 131% to 141 in FY20 (FY19: 61 new cases). Investment in cases on the balance sheet increased by 78% to £32.4m in FY20. Only £2.0m of the increase is accounted for by the encouraging progress on the Cartel Cases. As at 31 March 2020, there were 152 live cases in progress, an 81% increase (FY19: 84 live cases in process). At the time of writing we currently have 200 live cases in progress.

Realised revenue was 42% of total revenue (FY19: 52%). The proportion of realised revenue is lower this year due to the very high level of new investment activity, following the roll out of the regional in-house legal team. We are delighted with the current portfolio of live cases and, as noted in the CEO Report, the current FY20 vintage is delivering even stronger MoM and ROI returns than we have achieved in earlier vintages. However, the normal caveat for litigation funding applies - it is naturally very difficult to predict when cases will reach a successful conclusion and accordingly the blend between realised and unrealised gains will change from year to year. To date, our model has consistently delivered strong and fast investment returns over many years and spread over many granular cases. We have every expectation that this will remain to be the case. The one exception is the Cartel Cases. They are unique in our portfolio and will take longer to realise but the potential returns are highly attractive.

In the majority of cases (excluding Cartel Cases) this year's unrealised revenue becomes next year's realised revenue, as our average case duration is circa 12 months. When a case is fully completed, revenue is then recognised as realised and previously unrealised gains on that case are reversed.

It should be noted that the full recovery on a purchased case is recognised in revenue (the share going to the insolvent estate is a cost of sale). However, on funded cases, only the Company's share of the proceeds plus our cost recovery is counted as revenue. The insolvent estate's share of a recovery on a funded case does not feature in our accounts.

The following table illustrates the growth in cases being purchased by the Company, rather than funded:

 

Totals

Purchased

Purchased

Funded

Funded

 

 

Number

%

Number

%

FY19

61

55

90

6

10

FY20

141

113

80

28

20

 

As can be seen above, the proportion of our new cases purchased has remained high at 80% of new cases signed (from 90% in FY19). Whilst there will be year on year fluctuations, we expect the proportion of purchased cases to remain the strongly dominant category.

Cost of sales

Cost of sales comprises: legal costs on realised cases, the initial payments made to insolvent estates on our realised case investments (both purchased and funded) and payments to insolvent estates on successful realisations of purchased cases. Cost of sales excludes payments made directly to the insolvent estates on completed funded cases.

Gross profit

Gross profit grew by 43% to £14.4m (FY19: £10.1m). Our gross profit margin increased to 77% (FY19: 73%). The growth in gross profit reflects the movement towards larger cases, in both realised and unrealised gains. It also reflects the increased number of live cases in the Company's investment portfolio.

Movement in gross profit split between gross profit on realised cases and on unrealised cases is as follows:

 

FY20

 

FY19

 

 

£000s

 

£000s

 

Gross profit on realised cases

3,750

 

3,463

 

Gross profit on unrealised cases

10,640

 

6,623

 

Total

14,390

 

10,086

 

 

The table above shows that realised gross profits grew by 8.3% from FY19 to FY20, whilst unrealised gross profits grew by 61%.

We analyse gross profit into the separate categories of funded and purchased cases. Our strategic preference is to purchase cases rather than fund them. Generally, our Insolvency Practitioner clients, where possible, prefer the Company to purchase cases as this gives them and the insolvent estate fuller protection from any potential adverse costs. It also provides the Company with full operational control of the case through the litigation process.

 

FY20

%

FY19

%

 

£000s

 

£000s

 

Gross profit on funded cases

4,689

32

3,606

36

Gross profit on purchased cases

9,701

68

6,480

64

Total

14,390

100

10,086

100

 

Administrative expenses

Administrative expenses increased by 59% to £4.6m (FY19: £2.9m) and increased marginally as a proportion of gross revenue from 21% to 25%.

The increase in Administration expenses was primarily a result of increases in staff costs, as the Company recruited a regional network of in-house lawyers to service increased activity. Staff numbers have increased from twelve as at 31 March 2019 to 19 as at 31 March 2020, as the Company rolled out its promised regionalisation programme, which has led to a significant increase in enquiries and new cases. Our marketing costs have increased as we have undertaken business development activities, both in London and across the regions, in order to increase our market share and secure a greater level of enquiries. We have continued with our valuable sponsorship rights with the three key industry regulators and trade associations: The Institute of Chartered Accountants in England and Wales, R3 (the insolvency practitioners' professional association) and the Insolvency Practitioners Association.

Statutory operating profit before non-recurring items (Earnings Before Interest and Tax)

Operating profit before non-recurring items grew by 36% to £9.8m (FY19: £7.2m) with the operating margin improving to 52% (FY19: 52%). There were no exceptional items in FY20. In FY19, the business incurred exceptional IPO costs of £882k.

Finance costs

The Company agreed a £20m debt facility with HSBC in December 2018 to facilitate the growth of its case load in the future. The Company pays a 0.7% commitment fee on any unused facility with HSBC. As at 31 March 2020, £8.0m of the £20m HSBC facility had been drawn in the month of March.

During the year, the Company incurred £0.4m of finance costs (FY19: £0.4m). Loan interest amounted to £0.2m (FY19: £0.2m) and the remaining costs of £0.2m (FY19: £0.2m) comprised the amortisation charges of the costs of setting up the facility. The unamortised costs of £0.5m in the balance sheet are being amortised over the four-year life of the facility.

Profit before tax

Profit before tax has increased by 59% to £9.5m (FY19: £5.9m). The Company's pre-tax profit margin has increased from 43% to 51%.

Taxation

The Company's effective tax rate is 19%. The Company will discharge its corporation tax liabilities over the next few months.

Profit after tax

Profit after tax has increased by 63% to £7.6m (FY19: £4.7m). The post-tax margin has increased from 34% to 41%.

Earnings per share

As disclosed in Note 12, the restated earnings per share increased by 42% from 12 pence to 17 pence.

Investment in cases

The Company was managing 152 live case investments as at 31 March 2020, compared to 84 live cases as at 31 March 2019. The split between Purchased and Funded cases at these dates is as follows:

 

As at 31 March 2020

As at 31 March 2019

Funded

29

19%

13

15%

Purchased

123

81%

71

85%

Total

152

100%

84

100%

 

The total investment in cases amounted to £32.4m in FY20, an increase of 78% (FY19: £18.2m). Investment in cases are shown at fair value, based on the Company's estimate of the likely future realised gross profit, plus costs incurred. Case valuations are reviewed on a monthly basis but are only updated when there are developments in the case. Case valuations can be reviewed downwards, as well as upwards.

Management, following discussion on a case by case basis with the in-house legal team, amend valuations of cases each month end to accurately reflect management's view of fair value. In addition, at the interim and final reporting periods, a sample of material valuations are corroborated with the external lawyers working on the case, who provide updated legal opinions as to the current status of the case. The Company does not capitalise any of its internal costs, these are fully expensed to the Statement of Comprehensive Income as incurred.

Trade receivables, stock and cash conversion

Trade and other receivables have risen to £5.9m (FY19: £3.8m) of which £0.2m is non-current. As at 31 March 2020, the Company has lent £0.5m as a loan secured on property to an Insolvency Practitioner, this receivable loan generates interest of 10% in Year 1 and 12% in Year 2 and is included within the £5.9m receivables balance.

Turning to trade receivables, many of the realisations achieved are paid by the debtor promptly, especially where the debtor is a large company, an insurance company or a wealthy individual. However, in some cases, the debtor is dependent on selling assets to realise cash or pay the award or settlement and hence cash realisation can be delayed for some months. Where appropriate, the Company will secure its position by obtaining charging orders over the relevant assets. In smaller cases, the Company sometimes accepts payments on an instalment arrangement. Given the significant increase in number of cases completions in FY20, an increase in trade receivables was expected. However, the Company monitors outstanding debtors very closely. Based on realised revenue and receivables as at 31 March 2020, the Company is converting debtors into cash in 244 days, compared to 152 days as at 31 March 2019.

On one funded case, we successfully supported a Trustee in Bankruptcy in obtaining a Court order that resulted in a valuable London property being returned into the bankrupt's estate. As the Trustee in Bankruptcy was under pressure to distribute this value to the creditors, Manolete obtained an independent, third-party valuation of the property and acquired it for cash at that value. This property was sold during FY20 for a profit of £7k and the full cash proceeds were received in FY20.

Management assess the bad debt requirement based on a case by case review of outstanding debtors. A bad debt provision of £420k is held as at 31 March 2020 against specific debtors where there is concern over recoverability and a further 2% general provision has been raised against net debtor balances in total, excluding those with specific provisions.

Cashflow

A summary of our cash flows for the year is presented below:

 

FY20

FY20

Restated

FY19

Restated

FY19

 

£'000

£'000

£'000

£'000

 

 

 

 

 

Net opening cash

 

9,692

 

5,938

Operating cashflow for the year

1,201

 

667

 

Investment in new cases

(4,098)

 

(2,447)

 

Net cash flow after operating and investments

 

(2,897)

 

(1,780)

 

 

 

 

 

Working capital

 

(1,447)

 

(117)

 

 

 

 

 

Dividends and interest payments

 

(1,031)

 

(409)

 

 

 

 

 

Corporation tax - current year

(2,231)

 

 

 

Corporation tax - prior year

(1,200)

 

 

 

Corporation tax total

 

(3,431)

 

-

 

 

 

 

 

Other cash items

 

(41)

 

(9)

 

 

 

 

 

Net inflow of IPO proceeds

 

-

 

6,069

 

 

 

 

 

Net closing cash balance

 

845

 

9,692

 

I would like to make a number of observations in relation to our annual cash flow: operating cash flow for the year is positive £1.2m with cash inflows generated from completed cases exceeding payments to IPs and legal costs incurred on those cases and overheads payments.

In addition, the business invested £(4.1)m in open cases, comprising legal costs on both new and existing cases. As our trade debtors increased our working capital represents a negative cash movement. Whilst corporate cash flows, comprising dividends, interest and corporation tax together represented a £(4.4)m cash out flow.

In relation to corporation tax payments, in FY20 we incurred higher than usual cash outflows as a result of payment of prior year corporation tax on unrealised revenue (previously the Company did not pay corporation tax on unrealised revenue) and this represents a catch-up payment.

Management monitors cash on a weekly basis, both in terms of receipt of debtors, payment of legal costs by case and overhead payments and also over an 18 month period for working capital purposes. The CFO reports monthly cash flows to the board.

The timing of the cash inflow from settled cases differs from case to case, with some cases settling in full on the day of completion, some cases arranging payment terms as part of the settlement (usually monthly payments but can be quarterly) and in a small number of settled cases receipt of cash may be dependent on a sale of the defendant's property.

We pay corporation tax on a quarterly basis based on the previous quarter's profit before tax. Our corporation tax liability is based on both our realised and unrealised elements of profit.

Borrowings and loans

The Company has drawn down £8.0m of its HSBC loan facility and is financed by this loan and retained profits. The net proceeds from the IPO of £14.6m were received in December 2018 and have been deployed in the business, investing in cases. The Company has cash reserves of £8.4m as at 31 March 2020 which are available to both respond to any uncertainty over the Covid-19 virus and to deploy on new case investment. It also has £12m available of the £20m facility with HSBC and this facility and the cash reserves will be used to finance the growth of the case portfolio over the next few years.

 

 

Mark Tavener

Chief Financial Officer 

 

Strategic Report

 

The Directors present their strategic report for the year ended 31 March 2020.

 

Strategy and Business Model

 

The Company's strategy for growth and its business model are described in detail on the Company's website, www.manolete-partners.com.

On pages 17 to 18, we have set out the principal risks which may present challenges in executing the business model and delivering the strategy.

 

The financial statements for the year ended 31 March 2020 represent a very satisfactory out-turn for the business. Year-on-year Operating Profit before non-recurring items and tax and interest grew 36% to £9.8m and net assets grew 25% to £34.9m.

 

The number of employees was 19 at the end of the financial year.

 

The business continues to grow apace, at the financial year-end the cumulative number of signed litigation investments has grown to 420 cases. Out of 152 live cases at the financial year-end, 123 of these are purchased cases.

 

Financial Key Performance Indicators

 

 

Year Ended

31 March 2020

 

Year Ended

31 March 2019

% change

 

£000s

 

£000s

 

Revenue

18,682

 

13,772

36%

Gross profit

14,390

 

10,087

43%

Operating profit before non-recurring items

9,804

 

7,212

36%

Profit after tax

7,615

 

4,664

63%

Value of investments

32,415

 

18,197

78%

 

Non-Financial Key Performance Indicators

 

 

Year Ended

31 March 2020

 

Year Ended

31 March 2019

 

 

 

 

 

No.

 

No.

 

 

 

 

Number of signed litigation investments

420

 

279

 

 

 

51%

Live cases

152

 

84

 

 

 

81%

Purchased cases

123

 

71

 

 

 

73%

Funded cases

29

 

13

 

 

 

123%

 

The improvement in key performance indicators is analysed in the Report of the Chief Executive Officer on pages 5 to 9 and the Report of the Chief Financial Officer on pages 10 to 14.

 

Outlook and current trading

 

We are confident we have invested in a portfolio of cases that will produce attractive returns for the Company. We are seeing strong growth in new case enquiries, which give us confidence in our future prospects. 23 cases have been completed (including partial completions) since the year end and the current number of live cases is 200 compared to 152 at the FY 20 year-end. Furthermore, the average size per case continues to rise.

 

As highlighted in the CEO Report, the business adjusted rapidly and successfully to the challenges presented by Covid-19. The Board believes that the inevitable economic dislocations caused by the crisis are likely to lead to further increases in case referrals to the Company.

The Board has considered the Going concern status of the business both in relation to Covid-19 and in general and has concluded that it is appropriate for the accounts to be prepared on a going concern basis.

 

We believe that the business is very well-positioned to consolidate its leadership position in the insolvency litigation financing market. We raised £14.6m (net of expenses) at the IPO and we have successfully deployed these funds to grow our case-load of investments. We believe that the IPO has raised our profile significantly in our marketplace, and we have also recruited an outstanding team of in-house lawyers to strengthen our regional network, as promised at the IPO.

 

The Company has made a strong start to FY21 and we look forward to a promising future.

 

 

On behalf of the Board:

 

Steven Cooklin

Chief Executive Officer

 

 

Principal risks and uncertainties

 

The Board is responsible for developing a comprehensive risk framework and a system of internal controls. We have identified the following as the principal risks and uncertainties the Company faces.

 

Risk Activity

Principal Risk

Impact

Mitigation

Market Risk

Inability to continually and successfully attract, select and pursue investments in the UK insolvency litigation market.

Failure to attract enough cases to pay our overheads.

The Company focuses on well-established case selection screening procedures, rigorous internal and external cost controls, and close attention to the adequacy of liquidity in the business to comfortably support our case cost profile at all times.

Staff Risk

Over-reliance on key staff and inability to recruit new high-quality staff.

If key staff become unavailable, poor operational decisions could be made. If the right calibre of new staff cannot be recruited, expansion could be limited.

Key man life insurance on the CEO. Recruitment of experienced in-house lawyers. More delegation to key staff. Comprehensive and vigorous recruitment procedures.

Litigation Risk

Unexpected Court decisions in cases proceeding to full trial.

Cases could be lost or recoveries could be worse than anticipated. Adverse legal costs (the defendant's costs) would become payable by the Company if the case was lost.

Press for early settlement through mediation and without prejudice settlement negotiations. Early abort of cases where unexpected, adverse evidence emerges. On purchased cases (the large majority of the Company's cases) we can abort the case if prospects deteriorate. On funded cases we can terminate funding.

 

 

 

 

Legal Costs Risk

Legal costs can turn out to be more expensive than anticipated.

Case recoveries are poorer than expected.

Press for early settlement through mediation and without prejudice settlement negotiations. Agree fixed fees with external lawyers for each stage of litigation.

Recovery Risk

It may be difficult to collect agreed settlements or judgements

The Company will suffer from bad debts

Rigorous net worth checks on defendants before cases are accepted. Securing charging orders over defendants' properties

Case Risk

Case defects emerge during the litigation process

The Company will suffer abortive legal and investment costs and adverse costs (paying the defendant's legal costs)

Rigorous legal review before cases are accepted and close supervision of live cases by experienced and competent in-house lawyers. On purchased cases (the large majority of the Company's cases) we can abort the case if prospects deteriorate. On funded cases we can terminate funding.

Relationship Risk

Relationships with key sources of enquiries may not be maintained (including important creditors such as banks and HMRC)

The rate of enquiries referred to the Company may slow down

Active marketing and engaging with insolvency practitioners and solicitors and creditor groups including HMRC

Funding Risk

The growth of our business out-strips the capital we have available to fund cases

The ability of the Company to accept new cases is limited

We have a strong capital position through our HSBC facility of £20m, of which we have drawn down £8m as at 31 March 2020.

Covid-19

Impact of the outbreak of the Covid-19 virus

Inability to work from the office, potential closure of the courts

The entire Company is effectively working from home with full access to the necessary tools and communication facilities to work effectively. The Courts system has largely adapted to video and telephone trials and we are successfully conducting mediations and Without Prejudice settlement meetings using video technology and telephone.

 

 

 

 

 

 

Board of Directors

Peter Bertram, FCA

INDEPENDENT NON-EXECUTIVE CHAIRMAN

Peter joined the Company in November 2018 as Non-Executive Chairman. He is also Non-Executive Director of the Science Group plc. From 2004 to 2015, he was Chairman of Phoenix IT Group plc. He has held a variety of senior Non-Executive positions in public companies in the security, IT and media sectors including AttentiV Systems Group plc, office2office plc, Anite Group plc, Timeweave plc and Psion plc. Peter was senior Non-Executive Director and chair of the audit committee at Microgen plc between 2006 and 2017. Peter is a Fellow of the Institute of Chartered Accountants and a Companion of the Chartered Management Institute.

Peter is a member of both the audit committee and remuneration committee.

Steven Cooklin, ACA

CHIEF EXECUTIVE OFFICER

Steven founded the Company in 2009 and is Chief Executive. Steven is a Chartered Accountant having qualified at Coopers and Lybrand in 1991. Steven has over 20 years' experience in corporate finance with National Westminster Bank, Calder Corporate Advisory Ltd and Hill Samuel Investment Bank and is a former Director of HSBC Investment Bank (Corporate Finance Division). Steven is an Associate Member of The Association of Business Recovery Professionals.

Mark Tavener, ACA

EXECUTIVE DIRECTOR

Mark joined Manolete as Chief Financial Officer and Executive Board Director on 7 October 2019. Mark is a Chartered Accountant with over 20 years of experience. The core of Mark's career has been with Deloitte in London in Corporate Finance. He also served a secondment period within Government. Following his time with Deloitte, Mark was appointed Finance Director of a FinTech start-up company IPSX. Most recently, Mark has been a Director in the RSM due diligence team leading diligence on financial services businesses in the mid-market.

Lee Manning, FCA

SENIOR INDEPENDENT NON-EXECUTIVE DIRECTOR

Lee joined the Company in November 2018 as a Non-Executive Director. Lee is a qualified accountant and a specialist in restructuring and insolvency. He is a licensed UK Insolvency Practitioner. Between 2004 and 2018 he was a partner at Deloitte LLP in Restructuring Services. From 1989 to 2004, he was a Partner at Kroll Buchler Phillips, practitioners in corporate recovery and restructuring. He is a Fellow of the Institute of Chartered Accountants and the Association of Business Recovery Professionals. In October 2018, Lee became a consultant for Resolve Group UK, a restructuring and advisory firm based in London.

Lee, who has recent and relevant accounting experience, chairs the audit committee. He is also a member of the remuneration committee.

Dr Stephen Baister

INDEPENDENT NON-EXECUTIVE DIRECTOR

Stephen joined the Company in September 2017 as a senior adviser and was appointed as a Non-Executive Director in November 2018. Stephen was appointed as a bankruptcy registrar (Judge) of the High Court in 1996 and as chief bankruptcy registrar in 2004. He retired in 2017. Stephen has also been consultant for Moon Beever LLP since November 2017. He has a PhD in Law and was admitted as a solicitor in 1981 and as a licensed Insolvency Practitioner in 1985. Stephen is a member of the Chartered Institute of Linguists, an honorary member of the Insolvency Lawyers Association and honorary Fellow of the Chartered Institute of Credit Management.

Stephen chairs the remuneration committee and is also a member of the audit committee.

 

Directors' Report

 

The Directors present their report with the financial statements of the company for the year ended 31 March 2020.

 

Principal Activities

 

The principal activity of the company during the period under review was the acquisition and funding of insolvency litigation cases.

 

The requirements of the business review have been considered within the Strategic Report.

 

Results and dividends

 

An analysis of the Company's performance is contained within the Strategic Report. The Company's income statement is set out on page 40 and shows the results for the year.

 

In respect of the financial year ended 31 March 2020 a final dividend of 3.00p (2019: 1.49p) per ordinary share has been recommended by the Directors. Subject to approval at the Company's annual general meeting, the dividend will be paid on 30 September 2020 to shareholders on the register on 11 September 2020. An interim dividend of 0.5p has been paid during the year.

 

Directors

 

The Directors of the Company during the year were:

 

Peter Bertram

Steven Cooklin

Mark Tavener (appointed 7 October 2019)

Stephen Baister

Lee Manning

Patrick Lineen (resigned 27 November 2019)

 

Further details about each of the current directors, their experience and qualifications can be found on page 19 to 20.

 

Political and charitable donations

The Company made no charitable donations during the year ended 31 March 2020 (2019: £nil)

 

Director's emoluments

Details of the Directors' emoluments, other reward arrangements and contractual terms are provided in the Remuneration Report on pages 31 to 34.

 

Going Concern

Management provided the Board with a financial forecast of the business for an 18 month period from June 2020 which was discussed at January's Board meeting. The Directors have considered the going concern basis in the preparation of the financial statements and have made an assessment of the Company's ability to pay its debts as they fall due and have also assessed the prospects and the principal risks facing the Company.

 

Furthermore, the Board has discussed the impact of Covid-19 on the business and its market in both late March and May. It continues to keep this matter under review. As our business operates in the insolvency market, any economic downturn is likely to lead to further insolvencies and related litigation cases. On an operational basis, the business has been able to fully function remotely with our in-house lawyers meeting online with IPs and external lawyers and continuing to progress cases. The Courts continue to function at first remotely but increasingly in person.

As evidence of this market view there has been an increase in the number of new case referrals in April and May 2020 and we continue to complete on cases in April, May, June. Based on this assessment, the Directors are of the opinion that the Company has adequate financial resources to continue in operation and meet its liabilities as they fall due, for the foreseeable future. Hence, the Directors believe it is appropriate to adopt the going concern basis in preparing the financial statements.

 

Financial Instruments

 

Disclosures in respect of the Company policy regarding financial instruments and risk management are contained in notes 27-28 to the financial statements.

 

Directors' third-party indemnity provisions

 

Pursuant to the Company's Articles of Association, the Directors and Officers of the Company benefit from an indemnity which is a qualifying third-party indemnity for the purposes of s. 236 of the Companies Act 2006. The indemnity was in force throughout the financial period and at the date of approval of the financial statements. The Company has also taken the opportunity to purchase Directors' & Officers' Liability Insurance.

 

Statement of disclosure to auditors

 

All of the current Directors have taken all the steps that they ought to have taken to make themselves aware of any information needed by the Company's auditors for the purpose of their audit and to establish that the auditors are aware of that information. The Directors are not aware of any relevant information of which the auditors are unaware.

 

RSM UK Audit LLP has expressed their willingness to continue in office and a resolution to re-appoint them will be proposed at the annual general meeting.

 

 

 

The report of the Directors was approved by the Board on 2nd July 2020 and signed on its behalf by:

 

 

 

Steven Cooklin

Chief Executive Officer

 

 

 

 

 

 

 

Statement of Directors' Responsibilities 

 

The Directors are responsible for preparing the Annual Report, in accordance with applicable laws and regulations.

 

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare Company financial statements in accordance with International Financial Reporting Standards ("IFRSs") as adopted by the European Union. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that year. The financial statements are required by law and IFRS as adopted by the EU to present fairly, the financial position and performance of the Company. The Companies Act 2006 provides in relation to such financial statements that references in the relevant part of that Act to financial statements giving a true and fair view are references to their achieving a fair presentation

 

In preparing these financial statements, the Directors are required to:

 

· select suitable accounting policies and then apply them consistently;

· make judgements and accounting estimates that are reasonable and prudent;

· state whether they have been prepared in accordance with IFRSs as adopted by the European Union, subject to any material departures disclosed and explained in the financial statements; and

· prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

 

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose, with reasonable accuracy, at any time the financial position of the Company and enable them to ensure that the financial statements comply with the requirements of the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Manolete Partners plc website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

 

 

 

 

Corporate Governance Statement

As the Company's Independent Non-Executive Chairman, it gives me great pleasure to set out this section of our report which describes how Manolete and its operations are governed and led by its Board of Directors.

The Board is responsible for governance, oversight and leadership of the business. It has delegated certain matters to committees and management but has also established a schedule of matters which, because of their importance to the Company, it will not delegate. These include the determination of strategy, various financial issues and controls including changes to share capital, dividends, major contracts and investments, approval of financial statements, risk assessment and management and internal controls.

Our Board is entirely committed to applying high standards of governance. As Chairman, I recognise I have a particular responsibility for ensuring our governance arrangements are thoughtfully designed, carefully implemented and transparently communicated.

Since the publication of the last set of accounts in 2019, the Company has further expanded its regional reach across the country with the appointment of senior lawyers. We are satisfied our existing methods of working, as described below, are effective and appropriate to the current size, nature, resources and prospects of the Company.We have endeavoured to ensure our governance is held to the highest standards. During 2019 the Board undertook its first formal annual evaluation exercise. In addition the Company has also drawn up its own Environmental, Social and Governance (ESG) Policy which demands the Company, its Directors and its employees operate in an honest, professional and ethical manner. The ESG Policy is published on the website and is essential for our reputation as well as building trust and respect with our key stakeholders including customers, business associates, employees, communities and shareholders.

A critical relationship for the Company is with the Insolvency Practitioner community. We take particular care that all staff clearly understand our reputation with IPs is a vital asset in a competitive market. The Board both supports and promotes high standards of conduct in order to safeguard and continually build on this positive culture. We believe the long-term interests of our investors and other stakeholders will be best served by behaving responsibly and gaining the trust of those we deal with on a day-to-day basis, in particular those we represent in pursuing their claims.

Since the company's successful IPO in December 2018, the Board has adopted the Quoted Companies Alliance Corporate Governance Code (the QCA Code or the Code) and is actively applying the ten principles of the Code, as described in the remainder of this statement and on our website.

 

 

Peter Bertram

Independent Non-Executive Chairman

 

 

 

 

 

 

Audit Committee Report

 

Audit Committee Remit and membership

To assist it in its review of financial statements, financial controls and risk management arrangements, the Board has established terms of reference constituting the Audit Committee which are available on the Manolete website.

The Committee is chaired by an independent Non-Executive Director, Lee Manning. Lee is a Fellow of the Institute of Chartered Accountants and has recent, relevant financial experience. Peter Bertram and Stephen Baister, who are both also independent Non-executive directors, are the other members of the Committee.

In this financial year, the Committee met on four occasions, including to review and approve a recommendation to the Board on the final results for the prior year, FY19; and to review and approve the interim results in respect of FY20. The Committee met with the Auditors in the absence of management.

Review of Financial Statements

During the year the Committee reviewed the interim statements and, since the year end, it has reviewed the full year financial statements. The purpose of these reviews is, amongst other things, to provide assurance to the Board on the integrity of the financial statements, the appropriateness of the accounting policies adopted and judgments made, and the adequacy of the financial and other controls in place within the business.

In particular, in arriving at its recommendations to the Board, the Committee took account of the views of the Auditor, as set out in a formal report to the Committee discussed with the Auditors, including discussions held in the absence of management. The Committee considered the accounting policies adopted and sought assurance from the Auditors and management that those policies were appropriate. In particular, in relation to the introduction of the new accounting standard IFRS16.

The Audit Committee noted that the Auditors had identified two key audit matters, namely investment valuation and recoverability of trade receivables.

The Committee noted that, notwithstanding management judgment was carefully exercised in agreeing current case valuations, a degree of uncertainty necessarily exists in such valuations as the outcome of cases cannot be guaranteed. The Committee was assured of the rigorous processes which are used by management to arrive at individual case valuations to ensure that valuations are adjusted as and whenever management's understanding of the likely outcome of a case changes. Accordingly, the Committee was satisfied that the judgments used were reasonable and the risk of either over- or under-statement of investment valuations and the associated revenue recognition was minimised as far as possible. The Committee also drew comfort from a comparison of past case valuations with actual recoverability levels which demonstrated that management have a strong track record of valuing cases within a sensible margin of actual outturns, notwithstanding the uncertainties which inherently exist within case outcomes.

The Committee also considered the recoverability of receivables, noting that case recoveries can be impacted by a number of factors and can also change over time. A constant check is maintained on the assets believed to be available to settle awards made. Although security over assets is not universally sought, charges over property and injunctions over disposal are used to limit risk on a case-by-case basis. In addition, it is recognised that a full assessment of all respondents' assets is not possible but that recoverability is calculated on the basis of known assets only, thereby providing some degree of mitigation. The Committee considered whether recoverability of receivables was likely to be significantly impacted by the Covid-19 crisis but was reassured by management's experience to date in this regard. The Committee examined the basis on which the Company's bad debt provision had been calculated and considered it in the light of work carried out by the Auditors to compare it to historical averages. Having considered the audit testing carried out and management's explanations on processes and controls, the Committee were satisfied that the judgments and estimates used to assess the recoverability of receivables were reasonable.

Through discussion of the audit scope, audit findings, financial controls and management responses, the Audit Committee satisfied itself that the risks identified through the audit, including the key audit matters, had been properly addressed.

Risk Management

The Committee has responsibility for reviewing the risk register and for satisfying itself that risk identification and management processes, including the Company's financial and other controls, are robust and sufficient to keep the risks faced by the business within the level which can be tolerated by the business and which fit with the Board's appetite for risk.

The Committee also reviewed, and agreed to recommend to the Board for approval, the summary of principal risks set out on pages 17 to 18.

Auditor appointment, independence and fees

Independent audit is an important source of assurance for investors and other stakeholders. The Committee is cognisant of the need to ensure the Auditors remain independent and objective in auditing the Company's financial statements.

The Committee considered the assurances provided by the Auditors with regards to independence, including processes to ensure that the Audit partner, manager and other team members are independent as well as the firm as a whole. The Committee was also satisfied that there were no other factors likely to impair the Auditors' objectivity.

Ethical Policies

High standards of conduct are a central part of the Company's ethos. In particular, the Board is committed to setting and leading a culture based on fairness to all those with whom the Company engages.

The Board has adopted a number of ethical policies, including an anti-bribery and corruption policy and a whistleblowing policy. The Audit Committee review these arrangements annually and also require management to report to it, at least once a year, on the implementation of those policies and on any incidents arising under them which may occur from time to time. No such incidents were reported to the Committee during the year ended 31 March 2020 or since.

 

Remuneration Committee

Consistent with the Board's commitment to transparent reporting, the disclosures below are provided on a voluntary basis in order to provide a clear and comprehensive summary of the Company's senior remuneration policies and practices.

This report and its contents have not been audited other than where indicated. 

Remuneration Committee composition and role 

 

The Remuneration Committee comprises the Company's independent Non-Executive Directors, Stephen Baister, who also chairs the Committee, Peter Bertram and Lee Manning.

The Committee's role is to ensure that the Company's senior remuneration practices are appropriate to the business and delivery of its strategic objectives. The Committee oversees the various elements of the executive Directors' pay and benefits, as well as the other terms to which Directors are subject. The Remuneration Committee's terms of reference are available on the Company's investor website.

Due to the small nature of the existing team, the Committee is able to make a detailed review of pay and conditions of staff across the business to ensure that full account can be taken of changes made to the remuneration arrangements elsewhere in the Company when considering and determining executive pay matters.

In the year ended 31 March 2020, the Committee met on six occasions to review its terms of reference, consider increases in basic pay effective from the start of the new financial year and to plan its approach to performance-related benefits.

The Committee shall consider seeking support from external advisers as necessary.

Remuneration policy 

 

The success of the business and delivery of long-term value to our shareholders rely on the services and expertise of our high calibre team. The remuneration policy is an important element of the Company's ability to attract and retain individuals who can contribute to Manolete's success.

The purpose and aim of the Company's remuneration policy is to ensure that senior executives are appropriately rewarded for the contributions they make to the business, whilst aligning their interests with delivery of the Company's strategic objectives and performance targets in a way which does not expose the business to unacceptable risk. This policy applies to the reward of both existing Directors and any Directors who may be recruited in the future. 

As well as basic salary, Executive Directors benefit from pension contributions, an annual performance-related bonus and long-term performance share awards. The Chief Executive Officer, Steven Cooklin, also benefits from private health insurance. Executive Directors are invited to participate in a performance-related CSOP. To enable the whole team to share in the success of the business and to align their interests with those of shareholders, the Company, at the discretion of the Remuneration Committee, invites all staff, who are eligible, to participate in the CSOP.

Annual bonus 

 

When reviewing the basis for annual bonus awards for the year ending 31 March 2020, the Committee has determined that payment of any bonus will be dependent on achievement of performance targets based on EBIT, realised profits and strategic measures. No Executive Director's bonus will exceed 100% of basic salary. Payment of maximum potential bonuses will require achievement of stretch targets. Threshold targets will need to be achieved for any bonus to be paid.

Cash bonuses may also be payable to other team members, dependent upon performance. 

Company Share Option Plan 

 

The Board has adopted the Manolete Partners Company Share Option Plan (CSOP) to enable conditional share awards to be granted, which may be subject to achievement of performance criteria. Typically, such targets are measured over a three-year performance period.

During the year to 31 March 2020, options were granted to the Executive Directors as set out in the table below. These options vest on a one-third per annum basis but may not be exercised, in normal circumstances, until the third anniversary of grant. More information on the CSOP can be found in note 24 to the financial statements.

Executive Director 

Number of shares under option 

Exercise price 

Steven Cooklin 

6,741

4.45

Mark Tavener

6,471

64,593

4.65

4.30

 

In subsequent financial years it is anticipated that the Remuneration Committee will make further CSOP awards, details of which will be disclosed at the time of grant. 

Executive Directors' service contracts

The Executive Directors have service contracts setting out the terms of their employment. Steven Cooklin's contract may be terminated on twelve months' notice and Mark Tavener's contract may be terminated on 6 months' notice. In each case, notice can be given by either party. During the year, Patrick Lineen retired from the business, there were no exit costs. Patrick left the business on 31 December 2019.

Non-Executive Directors

 

Remuneration of the Non-Executive Directors is determined by the Board as a whole, with the relevant Non-Executive Director taking no part in the discussions or decision in relation to his own fees. The Non-Executive Directors are not entitled to annual bonuses or employee benefits. Each of the Non-Executive Directors has a letter of appointment stating, amongst other things, annual fees, the time commitment expected for the role and that the appointment may be terminated by either party giving three months' prior written notice.

 

Directors' remuneration (audited)

The table below summarises the remuneration for each Director in the financial year.

Year ended 31 March 2020 

Basic 

salary 

£ 

Employer Pension contribution 

£ 

Bonuses 

£ 

Termination 

payments 

£ 

Other benefits 

£ 

Total 

£ 

Non-Executive Chairman 

Peter Bertram

75,000

0

0

0

0

75,000

 

 

 

 

 

 

 

Executive Directors 

Steven Cooklin 

285,000

11,400

49,750

0

2,882

349,032

Mark Tavener1

73,461

1,500

20,000

0

290

95,251

Patrick Lineen1 

97,000

3,880

0

0

0

100,880

Non-Executive Directors 

 

Stephen Baister

50,000

0

0

0

0

50,000

Lee Manning

50,000

0

0

0

0

50,000

Total Directors' remuneration for the year ended 31 March 2020 

630,461

16,780

69,750

0

3,172

720,163

 

1 The remuneration for Stephen Baister, Peter Bertram, Patrick Lineen and Lee Manning represents the amounts paid to them in respect of the part year from their date of appointment to 31 March 2019. In FY20, the remuneration for Patrick Lineen and Mark Tavener represent part years due to Patrick Lineen retiring from the business and Mark Tavener's recruitment.

The annual remuneration for the new Director is as follows:

· Mark Tavener £150,000

 

 

 

Directors' interests (as at 31 March 2020)

 

As at 31 March 2020, the interests of the Directors in ordinary shares, pursuant to options granted under the CSOP were as disclosed above. The interests of the Directors in ordinary shares held in their own name or in which they have a beneficial interest are disclosed below. Although the Non-Executive Directors hold shares, their holdings are at a level which does not impinge their independence.

Ordinary 

shares 

% of issued 

share capital 

Stephen Baister 

21,667

0.06

Peter Bertram

14,285

0.03

Steven Cooklin 

7,842,199

18.00

Lee Manning 

14,285

0.03

 

 

Statement of Comprehensive Income

 

 

 

 

 

Note

 

31 March

 2020

£000s

 

31 March 2019

£000s

Revenue

4

18,682

 

13,772

Cost of sales

 

(4,292)

 

(3,686)

Gross profit

 

14,390

 

10,086

 

 

 

 

 

Administrative expenses

8

(4,586)

 

(2,874)

Operating profit

6

9,804

 

7,212

Exceptional costs-IPO

 

-

 

(882)

 

 

 

 

 

Operating profit post-exceptionals

 

9,804

 

6,330

Finance income

9

89

 

1

Finance expense

9

(437)

 

(393)

 

 

 

 

 

Profit before tax

 

9,456

 

5,938

 

 

 

 

 

Taxation

11

(1,841)

 

(1,274)

 

 

 

 

 

Profit and total comprehensive income for the year attributable to the equity owners of the company

 

7,615

 

4,664

 

 

 

 

 

 

 

 

 

 

Earnings per share (Restated)

 

 

 

 

 

 

 

 

 

Basic (pence per share)

12

£0.17

 

£0.12

Diluted (pence per share)

12

£0.17

 

£0.10

 

The above results were derived from continuing operations.

 

The notes on pages 44 to 64 form part of these financial statements.

Statement of Financial Position

Company Number: 07660874

 

31 March

2020

 

Restated

31 March

 2019

 

Note

£000s

 

£000s

 

 

Non-current assets

 

 

 

 

Investments

13

7,136

 

5,100

Intangible assets

14

56

 

6

Trade receivables

17

443

 

-

Deferred tax asset

20

157

 

46

Total non-current assets

 

7,792

 

5,152

 

Current assets

 

 

 

 

Investments

13

25,279

 

13,097

Stock

15

-

 

 

447

IFRS16 Lease asset

16

221

 

-

Trade and other receivables

17

5,454

 

3,777

Cash and cash equivalents

18

8,371

 

9,692

Total current assets

 

39,325

 

27,013

 

 

 

 

 

Total assets

 

47,117

 

32,165

 

 

 

 

 

EQUITY AND LIABILITIES

 

 

 

 

Equity

 

 

 

 

Share capital

22

174

 

174

Share premium

23

4

 

4

Share based payment reserve

23

226

 

67

Special reserve

23

905

 

3,157

Retained earnings

23

33,613

 

24,613

Total equity attributable to the equity owners of the company

 

34,922

 

28,015

 

 

 

 

 

Non-current liabilities

 

 

 

 

Trade payables

19

213

 

-

Borrowings

21

7,526

 

-

Total non-current liabilities

 

7,739

 

-

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

19

4,235

 

4,150

Lease liabilities

16

221

 

-

Total current liabilities

 

4,456

 

4,150

Total liabilities

 

12,195

 

4,150

 

 

 

 

 

Total equity and liabilities

 

47,117

 

32,165

 

The financial statements were approved by the Board of Directors and authorised for issue on 2nd July 2020.

 

 

Steven Cooklin

Chief Executive Officer

The notes on pages 44 to 64 form part of these financial statements.

Statement of Changes in Equity

 

 

Share Capital

Share Premium

Share based payment

Special reserve

Retained Earnings

Total Equity*

Note

£'000s

£'000s

£'000s

£'000s

£'000s

£'000s

 

 

 

 

 

 

 

 

As at 1 April 2018

 

100

1,015

-

-

6,642

7,757

Comprehensive income

 

 

 

 

 

 

 

Profit for the year

 

-

-

-

-

4,664

4,664

Transactions with owners

 

 

 

 

 

 

 

Issue of ordinary shares

22

74

16,213

-

-

(37)

16,250

Transaction costs of share issue

 

-

(723)

-

-

-

(723)

Reduction of share premium account

23

-

(16,501)

-

3,157

13,344

-

Share based payment expense

23

-

-

21

-

-

21

Deferred tax on share-based payments

23

-

-

46

-

-

46

As at 31 March 2019

 

174

4

67

3,157

24,613

28,015

Comprehensive income

 

 

 

 

 

 

 

Profit for the year

 

-

-

-

-

7,615

7,615

Transactions with owners

 

 

 

 

 

 

 

Dividends

10

-

-

-

-

(867)

(867)

Transfer in relation to historic corp tax

 

-

-

-

(2,009)

2,009

-

Transfer in relation to creditors paid

 

-

-

-

(243)

243

-

Share based payment expense

 

-

-

48

-

-

48

Deferred tax on share-based payments

 

-

-

111

-

-

111

As at 31 March 2020

 

174

4

226

905

33.613

34,922

            

 

*attributable to the equity owners of the Company.

The notes on pages 44 to 64 form part of these financial statements.

 

Statement of Cash Flows

 

 

31 March

 2020

 

Restated

31 March 2019

 

£000s

 

£000s

Cash flows from operating activities

 

 

 

Profit before tax

9,456

 

5,938

Adjustments for other operating items:

 

 

 

Sale / (Purchase) of property

493

 

(447)

Investment in cases

(4,098)

 

(2,447)

Issue of borrowings

(500)

 

-

Adjustments for non-cash/non-operating items:

 

 

 

Fair value movements

(10,900)

 

(6,624)

Finance income

(89)

 

(1)

Legal costs on realised cases

1,599

 

1,387

Finance expense

445

 

393

Share based payments

(63)

 

21

Operating cashflows before movements in working capital

(3,657)

 

(1,780)

 

 

 

 

Changes in working capital:

 

 

 

(Increase) in trade and other receivables

(1,620)

 

(157)

Increase in trade and other payables

433

 

40

Cash used in operations

(4,844)

 

(1,897)

Corporation tax paid

(3,431)

 

-

Net cash used in operating activities

(8,275)

 

(1,897)

 

 

 

 

Cash flows from investing activities

 

 

 

Purchase of intangible assets

(50)

 

(6)

Finance income received

35

 

1

Net cash (used) in investing activities

(15)

 

(5)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issue of ordinary shares (net of expenses)

-

 

15,569

Proceeds from borrowings

8,000

 

-

Repayment of borrowings

-

 

(9,500)

Payment of borrowing facility set up costs

-

 

(189)

Dividends paid

(867)

 

-

Interest paid

(164)

 

(220)

Net cash generated from financing activities

6,969

 

5,660

 

 

 

 

Net (Decrease)/Increase in cash and cash equivalents

(1,321)

 

3,758

 

 

 

 

Cash and cash equivalents at the beginning of the year

9,692

 

5,934

Cash and cash equivalents at the end of the year

8,371

 

9,692

 

The notes on pages 44 to 64 form part of these financial statements.

 

1. Company information

 

Manolete Partners PLC (the "Company") is a public company limited by shares incorporated in England and Wales. The Company is domiciled in England and its registered office is 2-4 Packhorse Road, Gerrards Cross, Buckinghamshire, SL9 7QE. The Company's ordinary shares are traded on the AIM Market.

 

The principal activity of the Company is that of acquiring and funding insolvency litigation cases.

 

2. Summary of significant accounting policies

 

The principal accounting policies applied in the preparation of these financial statements are set out below. The policies have been consistently applied to all the years presented, unless otherwise stated.

 

2.1 Basis of preparation

 

The above audited financial information does not constitute statutory financial statements as defined in section 434 of the Companies Act 2006. The above figures for the period ended 31 March 2020 have been extracted from the Company's financial statements which have been reported on by the Company's auditors and received an audit opinion which was unqualified. The Company's statutory financial statements for the year ended 31 March 2019 have been lodged with the Registrar of Companies. These financial statements received an audit report which was unqualified and did not include any reference to matters to which the auditors drew attention by way of emphasis without qualifying their report or a statement under section 498(2) or section 498(3) of the Companies Act 2006. The financial statements for the year ended 31 March 2020 will be dispatched to the shareholders and filed with the Registrar of Companies. The preliminary announcement was approved by the Board and authorised for issue on 2 July 2020.

 

Cash flow presentation and restatement of 2019 Statement of Financial Position

 

Following discussion with our auditors and with the FRC, we have presented both our Investment in cases and a purchase for resale of a property as operating cash flows rather than cashflows from investing activities as disclosed in 2019. This adjustment is a re-classification between the operating and investing cash flow categories within the cash flow statement in both the current and prior year to better reflect the nature of the cashflows and has no impact on the (decrease)/increase in cash and cash equivalents during the year or the amount held at the year end. Furthermore, we have restated the 2019 Statement of Financial Position to reflect the long-term nature of the cartel case investments.

 

Measurement bases

 

The financial statements have been prepared under the historical cost convention. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

 

The preparation of the financial statements in compliance with adopted IFRS requires the use of certain critical accounting estimates and management judgements in applying the accounting policies. The significant estimates and judgements that have been made and their effect is disclosed in note 3.

 

2.2 Going concern

 

After making appropriate enquires, the Directors of the Company have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and for at least one year from the date of the signed financial statements. 

 

Furthermore, the Board has discussed the impact of Covid-19 on the business and its market in both late March and May. It continues to keep this matter under review. As our business operates in the insolvency market, any economic downturn is likely to lead to further insolvencies and related litigation cases. On an operational basis, the business has been able to fully function remotely with our in-house lawyers meeting online with IPs and external lawyers and continuing to progress cases. The Courts continue to function at first remotely but increasingly in person.

 

As evidence of this market view there has been an increase in the number of new case referrals in April and May 2020 and we continue to complete on cases in April, May and June. Based on this assessment, the Directors are of the opinion that the Company has adequate financial resources to continue in operation and meet its liabilities as they fall due, for the foreseeable future. Hence, the Directors believe it is appropriate to adopt the going concern basis in preparing the financial statements.

 

For these reasons, they continue to adopt the going concern basis in preparing the Company's financial statements.

 

2.3 Functional and presentation currency

 

The financial information is presented in the functional currency, pounds sterling ("£") except where otherwise indicated.

 

2.4 New standards, amendments and interpretations

 

New IFRS 16 'Leases' implementation

Manolete has adopted IFRS16 - Leases for the financial year ending 31 March 2020 and it has chosen to use the modified retrospective approach to adoption which means there are no restatements to the prior year figures.

IFRS 16 introduces a single lease accounting model, whereby the Company will recognise a lease liability and a right to use asset at 1 April 2019 for leases previously classified as operating and finance leases. Within the income statement rent expense is replaced by depreciation and interest expense.

The adoption of IFRS16 has resulted in a right to use asset of £221k with a corresponding lease liability of £221k, being recognised at 31 March 2020.

Instead of recognising an operating expense for its operating lease payments, the Company has instead recognised interest on its lease liabilities of £64k and amortisation on its right-of-use assets of £124k in FY20. As these expenses are deducted below EBITDA, this has increased reported EBITDA by the amount of its current operating lease cost, which for the year ended 31 March 2020 was approximately £189,000. Hence the adoption of IFRS16 has increased the EBITDA growth in the current period but not the comparator which is not restated.

In order to allow users of the accounts to see how the impact of IFRS16 has affected adjusted EBITDA, we present a reconciliation below:

Reconciliation of lease costs

 

 

2020

 

2019

Increase

 

£000s

 

£000s

 

Consistent with 2019 presentation and accounting policy

10,324

 

7,212

43%

Changes due to IFRS16 adoption

189

 

-

 

Consistent with 2020 presentation and accounting policy

10,513

 

7,212

46%

 

The adoption of IFRS16 has increased the percentage growth in EBITDA from 43% to 46% in FY20.

IFRIC 23 'Uncertainty over Income Tax Positions'

IFRIC 23, "Uncertainty over Income Tax Positions", clarifies how to recognise and measure current and deferred income tax assets and liabilities when there is uncertainty over income tax treatments. There is no impact on the accounts.

 

The Company does not expect any other standards issued by the IASB, but not yet effective, to have a material impact on the Company.

The following is a list of other new and amended standards which, at the time of writing, had been issued by the IASB but which are effective in future periods. The amount of quantitative and qualitative detail to be given about each of the standards will, much like the amount of detail given about IFRS 16, depend on each entity's own circumstances.

· Amendments to IFRS 9 Prepayment Features with Negative Compensation (effective 1 January 2019)

· Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures (effective 1 January 2019)

· Annual Improvements to IFRSs 2015-2017 Cycle (IFRS 3 Business Combinations and IFRS

joint Arrangements, IAS 12 Income Taxes, and IAS 23 Borrowing Costs) (effective 1 January 2019)

· IFRS 17 Insurance Contracts (effective 1 January 2021).

 

 

 

2.5 Revenue recognition

 

Revenue comprises two elements: the movement in fair value of investments and realised consideration. Realised consideration occurs when a case is settled, or a Court judgement received. This is an agreed upon and documented figure. The movement in the fair value of investments is recognised as Unrealised gains within Revenue. This is management's assessment of the increase or decrease in valuation of an open case. These valuations are estimated following the progress of a case towards completion and also reflect the judgement of the legal team working on the case (see Note3. Significant Judgements and Estimates). Hence, unrealised revenue is the movement in the fair value of the investments in open cases over a period of time.

 

When a case is completed the carrying value is a deduction to Unrealised income and the actual settlement value is recorded as Realised revenue.

 

Revenue recognition differs between a purchased case, where full recognition of the settlement is recognised as revenue (including the insolvent estate's share) and a funded case where only the company's share of a settlement is recognised as revenue. This differing treatment arises because the Company owns the rights to the purchased case.

 

As revenue relates entirely to financing arrangements, revenue is recognised under the classification and measurement provisions of IFRS 9.

 

 

2.6 Finance expense and income

 

Finance expense

 

Finance expense comprises interest on bank loans and other interest payable. Interest on bank loans and other interest is charged to the statement of comprehensive income over the term of the debt using the effective interest rate method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 

Finance income

Finance income comprises interest receivable on funds invested and other interest receivable. Interest income is recognised in profit or loss as it accrues using the effective interest method.

 

2.7 Employee benefits: Pension obligations

 

The Company operates a defined contribution plan. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. The Company has no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

 

The Company has no further payment obligations once the contributions have been paid. The contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

 

2.8 Intangible assets

 

Intangible assets are measured at cost and are amortised on a straight-line basis over their estimated useful lives. Amortisation is charged within administrative expenses in the statement of comprehensive income so as to write off the cost of assets over their estimated useful lives, on the following basis:

 

Website development costs: 33.3% of cost, once the website development is complete

 

2.9 Stock

 

Stock is held at the lower of cost or net realisable value.

 

 

2.10 Financial assets

 

Classification

 

The Company classifies its financial assets at amortised cost or fair value through profit or loss. Financial assets do not comprise prepayments. Management determines the classification of its financial assets at initial recognition.

Financial assets at amortised cost

 

The Company's financial assets held at amortised cost comprise trade and other receivables and cash and cash equivalents in the statement of financial position.

 

These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They arise principally through the provision of goods and services to customers (e.g. trade receivables), but also incorporate other types of contractual monetary asset. They are initially recognised at fair value plus transaction costs that are directly attributable to their acquisition or issue and are subsequently carried at amortised cost using the effective interest method, less provision for impairment.

 

Impairment of financial assets

 

Impairment provisions are recognised when there is objective evidence (such as significant financial difficulties on the part of the counterparty or default or significant delay in payment) that the Company will be unable to collect all of the amounts due under the terms receivable, the amount of such a provision being the difference between the net carrying amount and the present value of the future expected cash flows associated with the impaired asset.

 

Impairment provisions for trade receivables are recognised based on the simplified approach within IFRS 9 using lifetime expected credit losses. During this process the probability of the non-payment of the trade receivables is assessed. This probability is then multiplied by the amount of the expected loss arising from default to determine the lifetime expected credit loss for the trade receivables. For trade receivables which are reported net, such provisions are recorded in a separate provision account with the loss being recognised within administrative expenses in the statement of comprehensive income. On confirmation that the trade receivable will not be collectable, the gross carrying value of the asset is written off against the associated provision.

 

Investments

 

Investments in cases are categorised at fair value through profit or loss. Fair values are determined on the specifics of each investment and will typically change upon an investment progressing through a key stage in the litigation or arbitration process in a manner that, in the Directors' opinion, would result in a third party being prepared to pay an amount different to the original sum invested for the company's rights in connection with the investment. Positive material progression of an investment will give rise to an increase in fair value and an adverse progression a decrease. Management identifies and selects a number of material case valuations for external opinion. As such this year the valuation of a sample of material investments was underpinned by an external legal opinion, which confirms the Directors' valuation.

 

Valuation of investments

 

Determining the value of purchased and funded litigation requires an estimation of the value of such assets upon acquisition and at each reporting date. The future income generation of such litigation is estimated from known information and the opinion of external senior specialist counsel and solicitors. Valuations of each case, at the balance sheet date, are therefore arrived at by the Directors, considering counsel's, or external lawyer's, assessment of the chances of a successful outcome, the state of progress of the matter through the legal system and the Directors' assessment of all other risks specific to the case.

 

2.11 Financial Liabilities

 

The Company classifies its financial liabilities in the category of financial liabilities at amortised cost. All financial liabilities are recognised in the statement of financial position when the Company becomes a party to the contractual provision of the instrument. Trade and other payables and borrowings are included in this category.

 

 

Borrowings

 

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the income statement over the period of the borrowings using the effective interest method.

 

Borrowings are de-recognised from the balance sheet when the obligation specified in the contract is discharged, is cancelled or expires. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss as other operating income or finance costs.

 

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

 

 

Trade and other payables

 

Trade and other payables are initially recognised at fair value and subsequently measured at amortised cost. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

 

 

2.12 HSBC loan facilities

Arrangement fees in relation to a £10m loan facility originally set up with HSBC in January 2018 that was subsequently extended to a £20m facility with a term of four years from date of extension, in November 2018, are capitalised and amortised over the length of the loan facility, four years.

These capitalised costs of £473,939 as at 31 March 2020 have been netted off against borrowings in the Statement of Financial Position.

2.13 Provisions

 

A provision is recognised in the balance sheet when the Company has a present legal or constructive obligation as a result of a past event, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, when appropriate, the risks specific to the liability. The increase in the provision due to the passage of time is recognised in finance costs.

 

2.14 Share capital

 

Ordinary shares are classified as equity. There is one class of ordinary share in issue, as detailed in note 22. Incremental costs directly attributable to the issue of new shares are shown in share premium as a deduction from the proceeds, net of tax.

 

2.15 Income tax

 

Income tax for the years presented comprises current and deferred tax. Income tax is recognised in profit or loss except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity

 

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts.

 

Temporary differences are not recognised if they arise from a) the initial recognition of goodwill, and b) for the initial recognition of other assets or liabilities in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

 

Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income taxes levied by the same taxation authority on either the taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.

 

2.16Share-based payments

 

Where share options are awarded to directors or employees, the fair value of the options at the date of grant is charged to the statement of comprehensive income over the vesting period. Non-market vesting conditions are considered by adjusting the number of equity instruments expected to vest at each balance sheet date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

 

2.17 Exceptional items

 

Exceptional items are disclosed separately in the financial statements where it is necessary to do so to provide further understanding of the financial performance of the Company. They are items that are material, either because of their size or their nature, or that are non-recurring, and are presented within the line items to which they best relate. 

3. Significant judgements and estimates

 

The preparation of the Company's financial statements under IFRS as endorsed by the EU requires the Directors to make estimates and assumptions that affect the reported amounts of assets and liabilities at the statement of financial position date, amounts reported for revenues and expenses during the year, and the disclosure of contingent liabilities, at the reporting date. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the assets or liability affected in the future.

 

Estimates and judgements are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

 

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are detailed below.

 

Valuation of investments

 

Investments in cases are categorised as fair value through profit and loss. Fair values are determined on the specifics of each investment and will typically change upon an investment progressing through a key stage in the litigation or arbitration process in a manner that, in the Directors' opinion, would result in a third party being prepared to pay an amount different to the original sum invested for the company's rights in connection with the investment. Positive material progression of an investment will give rise to an increase in fair value and an adverse progression a decrease.

 

The key stages that an individual case passes through typically includes: initial review on whether to make a purchase or funding offer, correspondence from the Company in-house lawyer, usually via externally retained solicitors, to the opposing party notifying them of the Company's assignment or funding of the claim, a fully particularised Letter Before Action and an invitation to without prejudice settlement meetings or mediation, if the opposing party does not respond then legal proceedings are issued. Further evidence may be gathered to support the claim. Eventually a court process may be entered into. The progress of a case feeds into the Director's valuation of that case each month, as set out below.

 

In accordance with IFRS 9 and IFRS 13, the Company is required to Fair Value open cases at the half year and year end reporting periods, at 30 September and 31 March each year. The Company undertakes the following steps:

· On a weekly basis, the internal legal team report developments into the Investment Committee on a case by case basis in writing. Full team meetings then take place on a fortnightly basis to review progress on all live cases, on a case-by-case basis over several hours.

· On a monthly basis, the Directors adjust case fair values depending upon objective case developments, for instance: an offer to settle, mediation agreed, positive or negative legal advice. These adjustments to fair value may be an increase or decrease in value or no change required;

· At reporting period ends, a sample of open case investments for which written assessments are obtained from external solicitors or primary counsel working on the case on behalf of Manolete.

In all cases, a headline valuation is the starting point of a valuation from which a discount is applied to reflect legal advice obtained, strength of defendant's case, the likely amount a defendant might be able to pay to settle the case, progress of the case through the legal process and settlement offers.

 

Movements in fair value on investments in cases are included within revenue in the Statement of Comprehensive Income. Fair value gains or losses are unrealised until a final outcome or stage is reached.

At the year-end there were 174 open cases, of these 145 had a valuation of less than £100k. These cases are not expected to have an individually material impact on the business when they are settled. The remaining 29 cases make up £24.5m of the Investments and are material to the business, the significant judgements and estimates in their valuations at the balance sheet date were as follows:

1. Judgements:

1.1 The amount that cases are discounted to recognise cases being settled before they are taken to Court, based on the fact of each case and management's judgment of the likely outcome

2. Estimates:

2.1 All cases will be subject to the internal key stages and regular fair value review processes as described above. For the avoidance of doubt, the fair value review requires an estimate to be made by senior management based upon the facts and progress of the case and their experience. For a sample selected by the external auditors, an external opinion is requested from counsel or a solicitor who is working on the case which provides an independent description of the merits of the case. These assessments include various assumptions that could change over time and lead to different assessments over the next 12 months.

2.2 Future legal costs have been estimated on the likely time the case will take to complete, ranging between 6 to 18 months (excluding the Cartel cases) and whether it will go to Court. Future results could be materially impacted if these original estimates change either positively or negatively.

2.3 Recovery of debts is based on the Company's ability to recover assets owned by the counterparty. Prior to taking on a case, a net worth review is undertaken of the defendant to ensure that they own sufficient assets. Cases that are settled without going to Court almost always recover in full, whilst those that result in Court cases are less predictable in terms of full recovery. 

2.4 The valuations assume that there is no recovery for interest and costs. If cases go to Court and result in a judgement in the Company's favour, it is likely that the Company will be awarded interest and costs.

 

Litigation is inherently uncertain. The Company seeks to mitigate its risk by: rejecting the majority of cases referred to it because the merits of the claim are considered weak or the defendant is considered not to have sufficient net worth and seeking to settle cases as early as possible. It also adopts a conservative approach to valuing cases. Nevertheless, the risk and uncertainty can never be completely removed. The key inputs are: the headline claim value, the likely settlement value, the opposing party's ability to pay and the likely costs in achieving the judgment. These inputs are inter-related to an extent.

Sensitivity analysis has not been included, due to the vast amount of inputs and number of variables which are inherently specific to each case, making it impossible to provide meaningful data. Whilst the Board considers the methodologies and assumptions adopted in the valuation are supportable, reasonable and robust, because of the inherent uncertainty of valuation, it is reasonably possible, on the basis of existing knowledge, that outcomes within the next financial year that are different from the assumptions could require a material adjustment to the carrying amount of the £32.9m of investments disclosed in the balance sheet.

However, as an indication we note that a 10% increase / (decrease) in the fair value of our top 20 cases would result in an increase / (decrease) in the fair value investment of +/- £1.6m.

Recoverability of trade receivables

Manolete's business model involves the provision of services for credit. The Company normally receives payment for services it has provided once a claim has been pursued and settled or decided in Court.

The average time from taking on a case to settlement is c.12 months although this can vary significantly case to case. As part of the settlement agreement, the timing of payment of the award by the defendant to Manolete is agreed, this is a legally binding document. Payments can be received in full on the day of settlement or in instalments over a period of time, as pre-agreed.

Recovery of these balances is closely reviewed by management and action, where appropriate, will be taken to pursue any late payments. A specific bad debt provision is raised over debtors where recoverability is a concern and an expected credit loss of 2% of the remaining debtor balances has also been raised to reflect possibly other unknown recoverability events.

 

 

4. Segmental reporting

 

During the year ended 31 March 2020, the revenue was derived from cases funded on behalf of the insolvent estate and cases purchased from the insolvent estate, which are wholly undertaken within the UK. Where cases are funded, upon conclusion, the Company has the right to its share of revenue; whereas for purchased cases, it has the right to receive all revenue, from which a payment to the insolvent estate is made. Revenues arising from funded cases and purchased cases are considered one business segment and are considered to be the one principal activity of the Company. All revenues derive from continuing operations and are not seasonal in nature.

 

Net realised gains on investments in cases represents realised revenue on completed cases.

 

Fair value movements includes the increase / (decrease) in fair value of open cases, the removal of the carrying fair value of realised cases (in the period when a case is completed and recognised as realised revenue) and the addition of the fair value of new cases.

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Net realised gains on investments in cases

7,782

 

7,148

Fair value movements (net of transfers to realisations)

10,900

 

6,624

 

18,682

 

13,772

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Arising from:

 

 

 

Funded cases

5,347

 

4,612

Purchased cases

13,335

 

9,160

 

18,682

 

13,772

 

5. Directors and employees

 

Staff costs for the Company during the year:

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Staff costs (including directors):

 

 

 

Wages and salaries

2,222

 

1,537

Social security costs

236

 

169

Other pension costs and benefits

115

 

50

 

2,573

 

1,756

 

Average monthly number of people (including executive and non-executive directors) employed by activity:

 

 

31 March 2020

 

31 March 2019

 

No.

 

No.

Directors (executive and non-executive)

5

 

3

Management and administration

14

 

9

 

19

 

12

 

 

 

 

 

5. Directors and employees (continued) 

 

Directors' emoluments:

 

 

31 March

2020

 

31 March 2019

 

£000s

 

£000s

Directors' emoluments:

 

 

 

Salaries and fees

745

 

608

Other pension costs and benefits

20

 

20

 

 

 

 

 

765

 

628

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Highest paid director:

 

 

 

Salaries and fees

335

 

350

Other pension costs and benefits

14

 

10

 

349

 

360

 

Management consider the directors to be the key management personnel.

 

 

6. Operating profit

 

Is stated after charging:

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Bad debt expenses

535

 

49

Share based payments

48

 

21

 

Following the implementation of IFRS16, lease costs are no longer charged to operating profit but are recognised as an interest charge and a depreciation charge. Costs of £189,000 in 2020 would previously have been charged to operating profit, see accounting policies for IFRS16 Leases.

Operating profit also includes profit on sale of a residential property of £7,090 in 2020.

7. Auditor remuneration

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Fee payable to Company's auditor and its associates for the audit of financial statements

62

 

61

 

 

 

 

Fees payable to Company's auditor and its associates for other services:

 

 

 

Interim Agreed Upon Procedures

10

 

10

Corporate finance services

-

 

168

Other taxation services

15

 

41

Total

87

 

280

Details of the Company's use of the Auditors for non-audit services, the reasons why the Auditors were used rather than another supplier and how the Auditors' independence and objectivity was safeguarded are set out in the Audit Committee Report on pages 29 to 30.

8. Analysis of expenses by nature

Internal legal costs are included within administrative expenses whereas external legal costs are either capitalised as Investments for open cases or recognised as cost of sales on completed cases.

The breakdown by nature of administrative expenses is as follows:

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Staff Costs, including pension and healthcare costs

2,573

 

1,756

Office costs

201

 

243

Other costs, including marketing costs and expected credit losses

1,812

 

875

Total administrative expenses

4,586

 

2,874

9. Finance income and finance expense

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Bank interest

39

 

1

Other loan interest

50

 

-

Total finance income

89

 

1

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Bank loan interest

57

 

179

Other loan interest (including interest on lease liabilities)

229

 

-

Bank loan charges

151

 

172

Other loan charges

-

 

42

Total finance expense

437

 

393

 

10. Dividends

Dividends paid during the financial year were as follows. No dividend was paid in FY19. There was no interim dividend in FY19.

 

31 March 2020

£000s

 

31 March 2019

£000s

Final dividend for the year ended 31 March 2019 of 1.49p per share, paid in September 2019

649

 

-

Interim dividend for the year ended 31 March 2020, of 0.50p per share, paid in December 2019

218

 

-

Total dividends paid during FY20

867

 

-

 

 

 

11. Taxation

 

31 March 2020

£000s

 

31 March 2019

£000s

Analysis of charge in year

 

 

 

Current tax charge on profits for the year

1,841

 

1,279

Adjustments in respect of prior periods

-

 

-

Income tax credit

1,841

 

1,279

Deferred tax

-

 

(5)

Total tax charge

1,841

 

1,274

 

 

The tax charge for the year differs from the standard rate of corporation tax in the UK of 19%. (2019: 19%). The differences are explained below.

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Profit on ordinary activities before tax

9,456

 

5,938

Profit on ordinary activities multiplied by the rate of corporation tax in the UK as above

1,797

 

1,128

Effects of:

 

 

 

Expenses not deductible

44

 

151

Provision for deferred tax release

-

 

(5)

Total taxation charge

1,841

 

1,274

 

12. Earnings per share

 

The basic earnings per share is calculated by dividing the profit attributable to ordinary equity holders by the weighted average number of ordinary shares outstanding during the year. Diluted earnings per share is calculated by dividing the profit after tax by the weighted average number of shares in issue during the year, adjusted for potentially dilutive share options.

 

The following reflects the income and share data used in the earnings per share calculation:

 

 

 

31 March 2020

 

Restated

31 March 2019

Restated

31 March 2018

 

£000s

 

£000s

£000s

Profit for the period attributable to equity holders of the Company

7,615

 

4,664

3,261

Weighted average number of ordinary shares

43,571,925

 

37,380,949

37,380,949

Earnings per share

0.17

 

0.12

0.09

 

 

 

31 March 2020

 

Restated

31 March 2019

Restated

31 March 2018

 

£000s

 

£000s

£000s

Profit for the period attributable to equity holders of the Company

7,615

 

4,664

3,261

Diluted weighted average number of ordinary shares

44,318,539

 

37,614,660

37,614,660

Diluted earnings per share

0.17

 

0.12

0.09

 

Reconciliation of number of shares and diluted shares at year end:

 

 

Number of shares, 31 March 2019

Net new share options issued

Number of shares, 31 March 2020

Base

43,571,425

-

43,571,425

Diluted

44,272,558

66,684

44,339,242

 

 

The earnings per share is diluted by options over ordinary shares, as detailed in note 24.

 

The earnings per share figures for 2019 and 2018 have been amended following a review of the Company's 2019 Financial Statements by the Financial Reporting Council. The figure presented for basic earnings per share of £0.32 in 2019 and £35.25 in 2018 should have been £0.12 and £0.09 respectively, as shown above. The figure presented for diluted earnings per share of £0.31 in 2019 and £35.25 in 2018 should have been £0.12 and £0.09 respectively. The difference arises to reflect a sub-division and subsequent consolidation of existing £1 shares, conversion of A shares into ordinary shares and a bonus issue which to ensure compliance with IAS 33 should have been adjusted retrospectively.

 

 

13. Investments

 

Non-current investments and current asset investments comprise the costs incurred in bringing funded and purchased cases to the position that they have reached at the balance sheet date. In addition, where an event has occurred that causes the Directors to revalue the amount invested, a fair value adjustment is made by the Directors based on Counsel's and the Directors' opinion, which can either be positive or negative (see Note 3.2 on accounting estimates).

 

 

2020

 

2019

 

£000s

 

£000s

As at 1 April 2019

18,197

 

10,555

Additions

4,917

 

2,405

Realisations

(1,599)

 

(1,387)

Fair value movement (net of transfers to realisations)

10,900

 

6,624

As at 31 March 2020

32,415

 

18,197

 

 

14. Intangible assets

Intangible assets comprised the costs of developing the Company's website. The website developments costs are amortised over the useful life of the website, which is estimated to be three years.

 

2020

 

2019

 

£000s

 

£000s

Website development costs

 

 

 

 

 

As at 1 April 2019

6

 

-

Additions

63

 

6

Amortisation charge

(13)

 

-

As at 31 March 2020

56

 

6

 

 

15.Stock

 

The Company purchased a house for re-sale in London in FY19, following the settlement of a case in unusual circumstances. The house was refurbished for a modest amount and was subsequently sold in November 2019 for a £7k profit. Hence, no stock is now held as at 31 March 2020.

 

 

 

 

 

2020

 

2019

 

£000s

 

£000s

As at 1 April 2019

447

 

-

Additions

-

 

447

Realisations

(447)

 

-

As at 31 March 2020

-

 

447

 

16. Right of use asset

The Company holds one lease, an office property lease for 21 Gloucester Place, London which expires in September 2021.

Consistent with IFRS16, the net present value of future lease rental payments is recognised as a liability and asset in the Statement of Financial Position, this has been calculated as £221k as at 31 March 2020. Future minimum commitments are £192k within one year with the remainder later than one year and not later than five years.

Under IFRS16, lease costs are charged to the income statement as interest and depreciation rather than as an administration cost. The depreciation charge for the year was £125k and the interest charge was £64k.

 

17.Trade and other receivables

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Amounts falling due in excess of one year:

 

 

 

Trade receivables

443

 

-

Amounts falling due within one year:

 

 

 

Other receivables

500

 

-

Prepayments

180

 

799

Trade receivables

4,774

 

2,978

 

5,454

 

3,777

 

It is the Company's policy to assess receivables for recoverability based on historical data available to management in addition to forward looking information utilising management's knowledge. The Directors consider that the carrying amount of trade and other receivables is approximately equal to fair value.

 

Included within prepayments for 2019 are the costs of setting up the HSBC facility, which are being amortised over the remaining life of the facility, which terminates on 30 November 2022. For 2020, these set-up costs have been offset against the drawn down loan as disclosed in note 19.

 

 

 

18. Cash and cash equivalents

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Cash at bank and in hand

8,371

 

9,692

 

8,371

 

9,692

 

All bank balances are denominated in pounds sterling.

19. Trade and other payables

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Amounts falling due in excess of one year:

 

 

 

Trade payables

213

 

-

Amounts falling due in one year:

 

 

 

Other taxation and social security

80

 

66

Corporation tax payable

1,006

 

2,557

Accruals and other creditors

3,149

 

1,527

 

4,235

 

4,150

 

 

20. Deferred tax liabilities/(asset)

 

 

2020

 

2019

 

£000s

 

£000s

At 1 April 2019

(46)

 

5

Released during the year

-

 

(5)

Asset created

(111)

 

(46)

At 31 March 2020

(157)

 

(46)

 

 

Deferred tax has been credited to equity reserve because these movements in deferred tax assets relate to releases and creation of share options.

 

 

21. Borrowings

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Non-current

 

 

 

Bank loans

7,526

 

-

 

7,526

 

-

 

 

 

 

 

 

 

 

Current

 

 

 

Bank loans

-

 

-

Total borrowings

-

 

-

 

Borrowings are shown net of HSBC set-up amortised costs of £474k. Hence, the gross borrowings are £8,000k as at 31 March 2020.

 

Reconciliation of liabilities arising from financing activities

 

 

 

1 April

2018

Cash flows

 Non-cash changes

31 March 2019

 

£000s

£000s

£000s

£000s

Bank borrowings

8,870

(9,500)

630

-

Other loans

-

-

-

-

Total liabilities from financing activities

8,870

(9,500)

630

-

      

 

 

 

1 April

2019

Cash flows

 Non-cash changes

31 March 2020

 

£000s

£000s

£000s

£000s

Bank borrowings

-

8,000

(474)

7,526

 

 

 

 

 

Total liabilities from financing activities

-

8,000

(474)

(7,526)

      

 

The Directors consider the carrying value of all financial liabilities to be equivalent to their fair value.

 

A £20,000,000 credit facility was provided on 30 November 2018 by HSBC Bank plc. The Company granted a fixed and floating charge over all of its assets in favour of HSBC Bank plc. The facility term is four years. The interest rate is LIBOR plus a maximum margin of 2.75%, depending on the Company's financial performance against agreed covenants.

 

The arrangement fees for this facility were included within prepayments in 2019 and have been offset against gross borrowings for 2020 following the drawdown of a portion of the facility.

 

 

22. Share capital

 

 

31 March 2020

 

31 March 2019

 

No.

 

No.

Allotted and issued

 

 

 

Ordinary shares of £0.004 each

43,571,425

 

43,571,425

 

 

 

 

 

Voting rights

 

The holders of ordinary shares are entitled to one voting right per share.

 

Dividends

 

The holders of ordinary shares are entitled to dividends out of the profits of the Company available for distribution.

 

 

 

23. Reserves

 

Share premium

 

Includes all current and prior year premiums received on issue of share capital, as follows:

 

 

 

2020

 

2019

 

£000s

 

£000s

As at 1 April

4

 

1,015

Proceeds from share issues

-

 

16,213

Transaction costs of share issue

-

 

(723)

Conversion into distributable reserves

-

 

(16,501)

As at 31 March

4

 

4

 

Share based payment reserve

 

Includes amounts recognised for the fair value of share options granted in accordance with IFRS 2.

 

Special non-distributable reserve

 

A special non-distributable reserve was created in FY19 to ensure there was sufficient reserves held within the Company to satisfy creditors at the time of a conversion of share premium to distributable reserves to allow a dividend to be paid in FY19. The balance on this reserve will decline to nil over time as creditors are paid.

 

Retained earnings

 

Includes all current and prior periods retained profits and losses.

 

24.Share options

The Company adopted the Manolete Partners Plc Company Share Option Plan on 21 November 2018, details of which are as follows:

 

The Company generally uses the Black-Scholes method to value share options when issued.

 

Details of the share options granted, exercised, lapsed and outstanding at the end of each year are as follows:

 

 

Number of share options

No.

Weighted average exercise price

£

 

Outstanding at beginning of year

701,133

1.12

Granted during the year

260,465

4.35

Forfeited/lapsed during the year

(193,781)

1.12

Exercised during the year

-

-

Outstanding at end of the year

767,817

2.22

Exercisable at end of the year

-

-

 

The weighted average contractual life of the options outstanding at the reporting date is 1 year and 11 months.

 

 

 

Exercise prices of share options outstanding at the end of the period:

 

Number of share options

No.

Exercise price

£

CSOP Options

154,764

2.58

Unapproved Options

613,053

2.13

 

 

 

The fair values of the options granted during the year were calculated using the Black Scholes model, with the following assumptions:

Risk free interest rate

0.5%

Expected volatility

33%

Expected dividend yield

1%

Life of the option

3 years

Weighted average share price

£4.00

 

25.Commitments and contingences

Capital commitments

There were no capital commitments at 31 March 2020.

 

26. Retirement benefits

 

The Company operates a defined contribution pension scheme for all qualifying employees. During the year, the Company charged £63,317 (FY19-£30,000) as employer's pension contributions. The outstanding pension creditor as at 31 March 2020 was £6,265 (FY19-£5,000).

 

27. Financial instruments - classification and measurement

Financial assets

 

Financial assets measured at amortised cost comprise other receivables, trade debtors and cash, as follows:

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Other receivables

500

 

-

Trade debtors

5,216

 

2,977

Cash at bank

8,371

 

9,692

 

14,087

 

12,669

 

 

 

 

Financial assets measured at fair value through profit or loss comprise of investments;

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Investments

32,415

 

18,197

 

32,415

 

18,197

 

 

 

 

 

     

 

 

 

27.Financial instruments - classification and measurement (continued)

Financial liabilities

 

Financial liabilities measured at amortised cost comprise accruals and other creditors and bank loans, as follows:

 

 

31 March 2020

 

31 March

 2019

 

£000s

 

£000s

Accruals and other creditors

3,149

 

1,527

Bank loans

7,526

 

-

 

10,675

 

1,527

 

 

 

 

The fair value of investments is determined as set out in the accounting policies in Note 2.

The fair value hierarchy of financial instruments measured at fair value is provided below:

 

Fair value hierarchy

 

31 March 2020

 

Level 1

Level 2

Level 3

 

£000s

£000s

£000s

Investments

-

-

32,415

 

 

 

32,415

 

 

 

 

 

 

 

31 March 2019

 

Level 1

Level 2

Level 3

 

£000s

£000s

£000s

Investments

-

-

18,197

 

-

-

18,197

 

 

 

 

 

     

28. Financial instruments - risk management

The Company's activities expose it to a variety of financial risks: market risk (including cash flow interest rate risk), investment risk, liquidity risk and credit risk. Risk management is carried out by the Board of Directors. The Company uses financial instruments to provide flexibility regarding its working capital requirements and to enable it to manage specific financial risks to which it is exposed.

 

The Company finances its operations through a mixture of equity finance, bank debt, cash and liquid resources and various items such as trade debtors and trade creditors which arise directly from the Company's operations.

 

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows associated with the instrument will fluctuate due to changes in market interest rates. Interest bearing assets including cash and cash equivalents are short-term liquid assets. It is the Company's policy to settle trade payables within the credit terms allowed and the Company does therefore not incur interest on overdue balances. No sensitivity analysis has been prepared as the impact on the financial statements would not be significant.

 

 

28. Financial instruments - risk management (continued)

The interest rate profile of the Company's borrowings is shown below:

 

 

31 March

 2020

 

31 March

2019

 

Debt

Interest

 

Debt

Interest

 

£

Rate

 

£000s

Rate

Floating rate borrowings

 

 

 

 

 

Bank loans

8,000

LIBOR and Margin of 1.75%

 

-

n/a

 

 

 

 

 

 

       

Liquidity risk

 

The Company seeks to maintain sufficient cash balances. Management reviews cash flow forecasts on a regular basis to determine whether the Company has enough cash reserves to meet future working capital requirements and to take advantage of business opportunities.

 

A maturity analysis of the Company's borrowings is shown below:

 

 

31 March 2020

 

31 March 2019

 

£000s

 

£000s

Less than one year

-

 

-

One to two years

-

 

-

Two to five years

8,000

 

-

 

8,000

 

-

 

 

Capital risk management

 

The Company is both equity and debt funded, and these two elements combine to make up the capital structure of the business. Equity comprises share capital, share premium and retained earnings and is equal to the amount shown as 'Equity' in the balance sheet. Debt comprises bank loans which are set out in further detail above and in note 19. The Company initially raised funds through an IPO in December 2018 and has drawn down £8m of a HSBC loan facility in 2020, the total facility is a £20m revolving credit facility with HSBC.

 

The Company's current objectives when maintaining capital are to:

 

· Safeguard the Company's ability as a going concern so that it can continue to pursue its growth plans.

· Provide a reasonable expectation of future returns to shareholders.

· Maintain adequate financial flexibility to preserve its ability to meet financial obligations, both current and long term.

 

The Company sets the amount of capital it requires in proportion to risk. The Company manages its capital structure and adjusts it in the light of changes in economic conditions and the risk characteristics of underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares or sell assets to reduce debt.

 

During the year ended 31 March 2020 the Company's strategy remained unchanged.

 

 

 

28. Financial instruments - risk management (continued)

Credit risk and impairment

 

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Company. The maximum exposure to credit risk is the carrying value of its financial receivables, trade and other receivables and cash and cash equivalents, as disclosed in the notes. The Company attempts to assess the probability of credit losses but seeks to minimise its credit risk by undertaking rigorous net worth checks before taking on a case. Credit defaults do not occur very often but occasionally counterparties may default on an agreed settlement, which involves payment by instalments.

 

The Company does not consider any concentration of risk within either trade or other receivables to be significant. The Company seeks to obtain charging orders over the property of trade receivables. The receivables' age analysis is also evaluated on a regular basis for potential doubtful debts. It is the Directors' opinion that no further provision for doubtful debts is required.

 

Credit risk on cash and cash equivalents is considered to be very low as the counterparties are all substantial banks with high credit ratings.

 

Currency risk

 

The Company is not exposed to any currency risk at present.

 

29. Related party transactions

 

Director and key management remuneration is disclosed in Note 5. There are no other related party transactions.

 

30. Ultimate controlling party

 

The Company has no ultimate controlling party.

 

31. Post balance sheet events

On Friday 26th June 2020, the judgment in relation to a purchased case was 'handed down' following a trial held and completed in March 2020. The judgment found in favour of the defendant on the two main aspects of the case and as such, an adjustment was posted to the accounts to write off the full fair value holding value as at 31 March 2020 and all associated capitalised costs, amounting to an adverse impact on the Statement of Comprehensive Income of £709k in FY20.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FR FFFSIDEIFIII
Date   Source Headline
26th Feb 20247:00 amRNSAppointment of Nominated Adviser and Broker
1st Dec 20237:00 amRNSBlock Listing Six Monthly Return
16th Nov 20237:00 amRNSHalf Year Results
9th Nov 20231:50 pmRNSNOTICE OF HY RESULTS, RETAIL INVESTOR PRESENTATION
25th Oct 20239:32 amRNSPresenting at Proactive One2One Investor Forum
18th Oct 20237:00 amRNSTrading Update
19th Sep 20235:15 pmRNSResult of AGM
1st Aug 202311:33 amRNSUpdate regarding the PACCAR Matter
1st Aug 20237:00 amRNSGrant of Share Options
20th Jul 20237:00 amRNSGrant of Share Options
7th Jul 20237:00 amRNSDirector/PDMR Shareholding
5th Jul 20234:57 pmRNSPosting of Annual Report and Notice of AGM
29th Jun 20237:00 amRNSThird Year: Band 1 Insolvency Litigation Funding
22nd Jun 20237:00 amRNSAudited results for the year ended 31 March 2023
13th Jun 202310:30 amRNSInvestor Presentation via Investor Meet Company
13th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSBlock Listing Six Monthly Return
22nd May 20237:00 amRNSRetail Investor Presentation at Mello2023
20th Apr 202312:30 pmRNSCORRECTION Further Trading Update
20th Apr 20237:00 amRNSFurther Trading Update
14th Mar 20231:49 pmRNSTrading Update
6th Feb 20237:00 amRNSHire of Former Government Counter-Fraud Expert
21st Dec 20229:11 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSBlock listing Six Monthly Return
10th Nov 20227:00 amRNSHalf Year Results
3rd Nov 20227:00 amRNSNotice of HY Results, Retail Investor Presentation
23rd Sep 20222:37 pmRNSUpdate on case
20th Sep 20222:00 pmRNSResult of AGM
9th Sep 20227:00 amRNSH1 Trading Update
1st Aug 202210:29 amRNSTotal Voting Rights
1st Aug 20227:00 amRNSGrant of Share Options and deferred bonus award
5th Jul 20225:04 pmRNSNotice of AGM
1st Jul 20227:00 amRNSBand 1 Ranking for Insolvency Litigation Funding
23rd Jun 20227:01 amRNSDirectorate Change
23rd Jun 20227:00 amRNSAudited results for the year ended 31 March 2022
16th Jun 20227:00 amRNSRetail Investor Presentation
15th Jun 20227:00 amRNSNotice of Results
1st Jun 20227:00 amRNSBlock Listing Six Monthly Return
3rd May 20227:00 amRNSTotal Voting Rights
26th Apr 20227:00 amRNSUpdate to recent Trading Statement & cash receipt
11th Apr 20227:00 amRNSTrading and business update
1st Mar 20227:00 amRNSTotal Voting Rights
6th Jan 20227:00 amRNSAppointment of Independent Non-Executive Director
4th Jan 20223:34 pmRNSTotal Voting Rights
3rd Dec 20217:00 amRNSGrant of Share Options
1st Dec 20217:00 amRNSTotal Voting Rights
30th Nov 202111:03 amRNSDirector/PDMR Dealings
26th Nov 202112:52 pmRNSBlock Listing Application
11th Nov 20217:00 amRNSHalf Year Results
3rd Nov 20217:00 amRNSNotice of Half Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.